WO2009149496A1 - Traitement du diabète, de ses complications et de troubles associés - Google Patents

Traitement du diabète, de ses complications et de troubles associés Download PDF

Info

Publication number
WO2009149496A1
WO2009149496A1 PCT/AU2009/000723 AU2009000723W WO2009149496A1 WO 2009149496 A1 WO2009149496 A1 WO 2009149496A1 AU 2009000723 W AU2009000723 W AU 2009000723W WO 2009149496 A1 WO2009149496 A1 WO 2009149496A1
Authority
WO
WIPO (PCT)
Prior art keywords
fatty acid
polyunsaturated fatty
compound
pkc
oxa
Prior art date
Application number
PCT/AU2009/000723
Other languages
English (en)
Inventor
Antonio Ferrante
Original Assignee
Central Northern Adelaide Health Service
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2008902922A external-priority patent/AU2008902922A0/en
Application filed by Central Northern Adelaide Health Service filed Critical Central Northern Adelaide Health Service
Publication of WO2009149496A1 publication Critical patent/WO2009149496A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/04—Nitro compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • the present invention relates to methods and compositions for inhibiting PKC enzymes, and to methods and compositions for inhibiting Nuclear Factor Kappa B.
  • the present invention also relates to the treatment of PKC- ⁇ mediated diseases and Nuclear Factor Kappa B mediated diseases including, for example, diabetes and complications thereof and atherosclerosis.
  • PKC is a serine/ threonine protein kinase which regulates a diverse range of cellular processes in an isozyme-spedfic manner. It plays a role in receptor desensitization, membrane structure, regulation of transcription, immune responses, and cell growth.
  • isozymes have been identified which are classified into classical (a, 61,, ⁇ 2, ⁇ ), novel ( ⁇ , ⁇ , ⁇ , ⁇ , ⁇ ), and atypical (L, ⁇ , ⁇ ) forms depending on their sensitivity to diacylglycerol (DAG) and calcium.
  • Classical PKCs are activated by calcium, DAG, phosphatidylserine (PS), unsaturated fatty acids and phorbol 12-myristate 13-acetate (PMA).
  • Novel PKCs are activated by DAG, PS, unsaturated fatty acids and phorbol esters such as PMA.
  • Atypical PKCs are activated by PS and phosphatidylinositides.
  • DAG Diacylglycerol
  • P1P2 phosphatidylinositol 4,5 bisphosphate
  • PKC In unstimulated cells, PKC is generally found in the soluble fractions and it translocates to the particulate fraction such as cellular membranes upon stimulation where it associates with proteins such as RACKs (receptor for activated C kinase) and STICKS (substrates that interact with C kinases).
  • RACKs receptor for activated C kinase
  • STICKS substrates that interact with C kinases
  • Nuclear factor kappa B is a cytoplasmic transcription protein and is an important mediator of the inflammatory response. It regulates the expression of interleukins, growth factors and cytokines, cell adhesion receptors and genes which regulate apo ptosis.
  • PKC and NFKB have been implicated in a number of diseases, conditions and states, such as diabetes and complications thereof, microvascular and macrovascular complications, retinopathy, nephropathy, and atherosclerosis. The effective prevention and/or treatment of such diseases, conditions and states remains problematic.
  • the present invention arises from the investigation of particular compounds in activation of protein kinase C enzymes and the activation of N FK[I
  • PKC is a serine/threonine protein kinase. Eleven isozymes have been identified which are classified into classical (a, ⁇ l, 62,, ⁇ ), novel (&,, ⁇ , ⁇ , ⁇ , ⁇ ), and atypical (C ⁇ , ⁇ ) forms depending on their sensitivity to diacylglycerol (DAG) and calcium.
  • Classical PKCs are activated by calcium, DAG,. phosphatidylserine (PS), unsaturated fatty acids and phorbol 12- ⁇ nyristate 13-acetate (PMA). Novel PKCs are activated by DAQ. PS, unsaturated fatty acids and phorbol esters such as PMA.
  • Atypical PKCs are activated by PS and phosphatidyiinositides.
  • PKC regulates a diverse range of cellular processes in an isozyme-specifie manner. It plays a role in receptor desensitization, membrane structure, regulation of transcription, immune responses, and cell growth.
  • DAG Diacylglycerol
  • P1P2 phosphatidylinositol 4,5 bisphosphate
  • Dc novo synthesis is the major mechanism by which DAG is increased in response to hyperglycemia and it has been shown that this elevation remains despite a reduction in glucose concentration.
  • PKC In unstimulated cells, PKC is generally found in the soluble fractions and it translocates to the particulate fraction such as cellular membranes upon stimulation where it associates with proteins such as RACKs (receptor for activated C kinase) and STICKS (substrates that interact with C kinases).
  • RACKs receptor for activated C kinase
  • STICKS substrates that interact with C kinases
  • PKC enzymes are generally as described in Protein Kinase C (Second Ed, ed. By Lodwijk V. Dekker, KIu were Academic/Plenum Publishers, 2004)
  • the present invention is directed to inhibition of PKC- ⁇ enzymes.
  • PKC- ⁇ enzyme as used throughout the specification is to be understood to mean a member of the classical isozymes of the PKC family of enzymes, being enzymes that are stimulated when diacylglycerol (DAC) and Ca 2 ⁇ accumulate in appropriately stimulated cells.
  • DAC diacylglycerol
  • PKC- ⁇ enzymes include the ⁇ l and ⁇ 2 isoform s.
  • the human ⁇ 1 isoform is provided in GenBank accession number NP_997700.
  • the human ⁇ 2 isoform is provided in GenBank accession number NP__002729,
  • Other PKC- ⁇ enzymes may identified by a method known in the art. Generally, a PKC- ⁇ enzyme has greater than
  • the level of similarity with the human PKC- ⁇ 1 enzyme from the PKC- ⁇ l enzymes from other species is as follows: dog (XP_547088>- 94.7%; rat (NP_036845) - 98.7%; mouse
  • PKC- ⁇ enzymes may be identified by methods known in the art.
  • the present invention provides a method of inhibiting activation of a PKC enzyme in a cell, the method including exposing the cell to an effective amount of a compound, or a salt or solvate thereof, selected from the group consisting of (i) a polyunsaturated fatty acid including an oxa and/or thia substitution at either or both of the ⁇ or ⁇ position of the polyunsaturated fatty acid; (ii) a polyunsaturated fatty acid covalently coupled to an amino acid; (iii) a polyunsaturated nitroalkene or nitroalkyne; (iv) a n-3 polyunsaturated fatty acid; and (v) a n-6 polyunsaturated fatty acid.
  • a compound, or a salt or solvate thereof selected from the group consisting of (i) a polyunsaturated fatty acid including an oxa and/or thia substitution at either or both of the ⁇ or ⁇ position of the polyuns
  • the PKC enzyme in the various embodiments of the present invention is a ⁇ isoform
  • the PKC- ⁇ enzyme is PKC- ⁇ l and/or PKC- ⁇ Z
  • the cell is a human or an animal cell.
  • animal cells include cells from the following: a mammal, a primate cell, a livestock animal (eg a horse, a cow, a sheep, a pig, or a goat), a companion animal (eg. a dog, a cat), a laboratory test animal (eg. a mouse,, a rat, a guinea pig, a bird, a rabbit), an animal of veterinary significance, or an animal of economic significance.
  • the cell is a retinal cell, a kidney cell, a pancreatic cell, a vascular cell, or a cell lining a blood vessel.
  • Examples of cell types include endothelial cells and mesangial ceils.
  • the cell in the various embodiments of the present invention may be a cell present in vivo or in vitro.
  • the cell may be part of a biological system, such as a cell present in vivo, for example a cell that is associated with a PKC- ⁇ mediated disease, condition or state.
  • a biological system such as a cell present in vivo, for example a cell that is associated with a PKC- ⁇ mediated disease, condition or state.
  • biological system is to be understood to mean any multi-cellular system and includes isolated groups of cells to whole organisms.
  • the biological system may be a tissue or organ, or an entire subject.
  • the term ''subject as used throughout the specification is to be understood to mean a human or animal subject.
  • the present invention includes within its scope veterinary applications.
  • the animal subject may be a mammal, a primate, a livestock animal (eg. a horse, a cow, a sheep, a pig, or a goat), a companion animal (eg. a dog, a cat), a laboratory test animal (eg. a mouse, a rat,, a guinea pig,, a bird, a rabbit), an animal of veterinary significance, or an animal of economic significance.
  • a livestock animal eg. a horse, a cow, a sheep, a pig, or a goat
  • a companion animal eg. a dog, a cat
  • a laboratory test animal eg. a mouse, a rat,, a guinea pig,, a bird, a rabbit
  • an animal of veterinary significance e.g. a
  • inhibiting activation of a PkC enzyme in a t ell mav include inhibiting transloc ation of a PKC enzyme in a cell from the cytoplasm to the particulate fraction
  • inhibiting translocation ot a PkC enzyme in a cell from the cytoplasm to the particulate fraction mav represent a new mode of therapeutic action for the treatment ol a number ot diseases, condition and states, including PkC mediated diseases conditions and states.
  • the compounds, salts or solvates thereof may be used to prevent and/or treat a number of diseases, conditions and states, including PKC- ⁇ mediated diseases, conditions or states in a subject.
  • Fxamples of PKC- ⁇ mediated diseases, conditions or states include (i) diabetes, or a complication thereof, including diabetic microvascular complications and/or diabetic macrovascular complications, diabetic retinopathy, diabetic nephropathy and diabetic uremia, (ii) ischemia/reperfusion injury, and complications thereof, (iii) atherosclerosis; (iv) restenosis; (v) tumour growth; and (vi) undesired or uncontrolled angiogenesis, including tumour-induced angiogenesis.
  • diabetes or a complication thereof, including diabetic microvascular complications and/or diabetic macrovascular complications, diabetic retinopathy, diabetic nephropathy and diabetic uremia, (ii) ischemia/reperfusion injury, and complications thereof, (iii) atherosclerosis; (iv) restenosis; (v) tumour growth; and (vi) undesired or uncontrolled angiogenesis, including tumour-induced angiogenesis.
  • the subject in the various embodiments of the present invention may be susceptible to, or suffering trom, a disease, condition or state that would benefit from inhibition of a PICC enzyme.
  • the present invention provides use of a compound, or a salt or solvate thereof, in the preparation ot a medicament tor preventing and/or treating a PKC-Ji mediated disease, condition or state in a subject, the compound being selected from the group consisting of (i) a polyunsaturated fatty acid including an oxa and/or thia substitution at either or both of the ⁇ or ⁇ position ot the polyunsaturated fatty acid, (ii) a polyunsaturated fatty acid covalently coupled to an amino acid; (iii) a polyunsaturated nitroalkene or nilroalkync, (iv) a n-3 polyunsaturated tally acid, and (v) a n-6 polyunsaturated fatty acid.
  • a polyunsaturated fatty acid including an oxa and/or thia substitution at either or both of the ⁇ or ⁇ position ot the polyunsaturated fatty acid
  • Nuclear tactor kappa B (KFKB) is a cytoplasmic transcription protein and is an important mediator of the inflammatory response. It regulates the expression of inter! eukins, growth factors and cytokines, cell adhesion receptors and genes which regulate apoptosis.
  • Nl'kJB exists as a heterodimer composed of 2 subunits. the most common being p50 (5OkDa) and p65 (65kDa). Other family members include e-rel ReIB and p52. Within the iytoplasm it remains inactive due to its interaction with the inhibirorv protein, Inhibitory kappa B (I ⁇ B- ⁇ , ⁇ or t).
  • KFKB Several factors have been recognised m activating KFKB such as the inflammatory mediators I MF, inlerleukin-1 (IL-I), bacterial lipopolysaccharide (LPS), advanced glycalion end products ( ⁇ Glis), and platelet- activating factor It is also activated by conditions such as hyperglycemia, shear stress, oxidi/ed lipids oxidant stress and hypoxia/reperfusion.
  • I MF inlerleukin-1
  • LPS bacterial lipopolysaccharide
  • ⁇ Glis advanced glycalion end products
  • platelet- activating factor It is also activated by conditions such as hyperglycemia, shear stress, oxidi/ed lipids oxidant stress and hypoxia/reperfusion.
  • KFKB inducing kinase KIK
  • IKB kinases IKKl/IKK ⁇ and lKK2/lKk ⁇ , XFMCVlKKy
  • IKB is subsequently ubiquitinated and degraded by the 26S proteasome.
  • MEKkI rnitogen-activated protein kinase/extraiellular signal- regulated kinase kinase-]
  • TGF transforming growth factor
  • TAKl transforming growth factor- ⁇ -mducible kinase
  • Akt protein kinase C- ⁇ and 0
  • N 1 FKB ac tivation is transient due to intracellular regulatory mechanisms.
  • the resynthesis of I ⁇ B ⁇ after phosphorylation results in shuttling of NFKB back to the cytoplasm where it is re-coupled with IKB and inactivated.
  • the present invention also provides a method of inhibiting activation of NF i ⁇ in a cell, the method including exposing the cell to an effective amount of a compound,, or a salt or solvate thereof, selected from the group consisting of (i) a polyunsaturated fatty acid including an oxa and/or tnia substitution at either or both of the ⁇ or ⁇ position of the polyunsaturated fatty acid; (ii) a polyunsaturated fatty acid covalently coupled to an amino acid; (iii) a polyunsaturated nitroalkene or nitroalkyne; (iv) a n-3 polyunsaturated fatty acid; and (v) a n-6 polyunsaturated fatty acid.
  • a compound,, or a salt or solvate thereof selected from the group consisting of (i) a polyunsaturated fatty acid including an oxa and/or tnia substitution at either or both of the ⁇ or
  • the ceil is selected from the group consisting of a retinal cell, a kidney cell, a pancreatic cell, and a vascular cell.
  • the cell is a present in a biological system, such as a human or animal subject, for example a human or animal subject is susceptible to, or suffering from a disease, condition or state associated with activation of NFi ⁇ , or a disease, condition or state that would benefit from inhibition of activation of NF K ⁇ .
  • the disease, condition or state is selected from one or more of the group consisting of (i) diabetes, or a complication thereof, including diabetic microvascular complications and/or diabetic macrovascular complications, diabetic retinopathy, diabetic nephropathy and diabetic uremia; (ii) ischemia/reperfusion injury, and complications thereof; (iii) atherosclerosis; (iv) restenosis; (v) tumour growth; (vi) undesired or uncontrolled angiogenesis, including tumour-induced angiogenesis; (vii) inflammatory disease; and (viii) cardiovascular disease.
  • diabetes or a complication thereof, including diabetic microvascular complications and/or diabetic macrovascular complications, diabetic retinopathy, diabetic nephropathy and diabetic uremia; (ii) ischemia/reperfusion injury, and complications thereof; (iii) atherosclerosis; (iv) restenosis; (v) tumour growth; (vi) undesired or uncontrolled angiogenesis, including tumour-induced angiogenesis
  • the present invention also provides a method of preventing and/or treating in a subject one or more of (i) diabetes, or a complication thereof; (ii) ischemia/reperfusion injury, and complications thereof; (iii) atherosclerosis; (iv) restenosis; (v) tumour growth; and
  • angiogenesis undesired or uncontrolled angiogenesis; the method including administering to the subject an effective amount of one or more compounds, or salts or solvates thereof, selected from the group consisting of (i) a polyunsaturated fatty acid including an oxa and/or thia substitution at either or both of the ⁇ or ⁇ position of the polyunsaturated fatty acid; (ii) a polyunsaturated fatty acid eovalently coupled to an amino acid; (in) a polyunsaturated mtroaJkene or nitroalkyne; (iv) a n-3 polyunsaturated fatty acid; and (v) a n-6 polyunsaturated fatty acid.
  • a polyunsaturated fatty acid including an oxa and/or thia substitution at either or both of the ⁇ or ⁇ position of the polyunsaturated fatty acid eovalently coupled to an amino acid
  • the present invention provides a method for preventing and/or treating diabetes and/or a complication thereof.
  • Diabetes is characterized by hyperglycemia and depressed metabolism of carbohydrate, protein and fat due to impairment of insulin secretion or resistance to insulin action. Diabetes may be classified into 'Type 1 and Type 2 diabetes, as well as other rarer forms of the disease. In contrast to type 1 diabetes, the onset of type 2 diabetes does not usually occur until adult years and there is no evidence of autoantibodies and no increase in frequency of HLA-DR3, or DR4. The onset of the disease is more insipid with individuals having milder symptoms of hyperglycemia with polyuria and polydipsia over a longer time period.
  • preventing/or treating diabetes and/or a complication thereof in a subject includes a reduction in glucose production by the subject.
  • a reduction in glucose production by the subject may include a reduction in gluconeogensis in the subject.
  • Gluconeogenesis is a pathway consisting of eleven enzyme-catalyzed reactions. The pathway can begin in the mitochondria or cytoplasm, depending on the substrate being used. Many of the reactions are the reversible steps found in glycolysis. Gluconeogenesis begins in the mitochondria with the formation of oxaloacetate through carboxylation of pyruvate. This reaction also requires one molecule of ATP, and is catalyzed by pyruvate carboxylase. This enzyme is stimulated by high levels of acetyl -Co A (produced in ⁇ -oxidation in the liver) and inhibited by high levels of ADP. Oxaloacetate is reduced to malate using NADH, a step required for transport out of the mitochondria.
  • Oxaloacetate is decarboxylatcd and phosphorylated to produce phosphoenolpyruvate by phosphoenolpyruvate carboxykinase.
  • One molecule of GTP is hydrolyzed to GDP during this reaction.
  • the next steps in the reaction are the same as reversed glycolysis.
  • fructose-1,6- bisphosphatase converts fructose-l,6-bisphosphate to fructose 6-phosphate.
  • Glucose-6- phosphate is formed from fructose 6-phosphate by phosphoglucoisomerase.
  • Glucose-6- phosphate can be used in other metabolic pathways or dephosphorylated to free glucose. Whereas free glucose can easily diffuse in and out of the cell, the phosphorylated form (gl ⁇ cose-6-phosphate) is locked in the cell, a mechanism by which intracellular glucose levels are controlled by cells.
  • the final reaction of gluconeogenesis, the formation of glucose, occurs in the lumen of the endoplasmic reticulum where glucose-6-phosphate is hydrolyzed by glucose-6-phosphatase to produce glucose.
  • Glucose is shuttled into the cytosol by glucose transporters located in the membrane of the endoplasmic reticulum.
  • a reduction of glucose production by the subject and/or a reduction in gluconeogenesis in the subject may be via inhibition of one or more of the enzyme- catalysed reactions of gluconeogenesis as described above.
  • complications of diabetes include polyuria and polydipsia. These conditions results in dehydration and physiologic stress with the elevation of stress hormones (adrenaline, Cortisol, growth hormone, glucagon). These counter- regulatory hormones antagonise the action of insulin and promote glycogenosis, gluconeogenesis, lipolysis and ketogenesis resulting in acceleration of metabolic decompensation and progression to ketoacidosis.
  • stress hormones adrenaline, Cortisol, growth hormone, glucagon
  • Microalbuminuria occurs when the kidney leaks small amounts of albumin into the urine. Microalbuminuria may be caused by an abnormally high permeability for albumin in the renal glomerulus. Microalbuminuria is diagnosed either from a 24-hour urine lolk'ction (20 to 200 ⁇ g/min) or, more commonly, from elevated concentrations (30 to 300 mg/T ) on at least two occasions. An albumin level above these values may be described as macroaJbuminuria or albuminuria.
  • the complication of diabetes contemplated herein kuludes one or more ot polydypsia, polyuria and/or muroalbuminuria.
  • Hyperglycemia may also result in biochemical changes which lead to microvascular and macrovascular complications of diabetes.
  • Macrovascuiar complications include coronary artery disease, atherosclerosis and peripheral vascular disease which can lead Io acute myocardial infarction, angina and poor wound healing.
  • Microvascular comput ations irulude nephropathy, neuropathy, and retinopathy which can result in end-stage kidney disease, impaired nerve conduction and blindness.
  • the method ot the present invention is directed to preventing and/or treating microvascular and macrovascular complications of diabetes.
  • Diabetics may also have abnormal lipid metabolism with elevated levels of free fatty acids and triglycerides. This lowers HDL (high density lipoprotein) levels. Both hypertriglyceridaemia and low HDL contribute to endothelial dysfunction. An elevated free fatty acid level in individuals is believed to contribute to insulin resistance in type 2 diabetes. Hyperglycemia induced biochemical changes along with the abnormal lipid metabolism and insulin resistance may result in endothelial cell damage, platelet activation and aggregation and increased coagulation factors which increases the risk of vascular thrombosis. This leads to coronary artery disease, cerebrovascular disease ie. stroke and peripheral vascular disease. In some embodiments, the present invention contemplates preventing and/or treating vascular compri cati ons of di abetes.
  • Hyperglycemia may also result in complications which alter blood vessel function, resulting in hacmodynamic changes and hyperfiltration through the glomeruli.
  • Pathological changes in the kidneys occur characterised by widening of the glomerular basement membrane and thickening of the mesangium.
  • the earliest indication of nephropathy is microalbuminuria which has a prevalence of 3.7-30.6% in type 1 diabetics. Approximately 1.6% of diabetics develop microalbuminuria per year.
  • TMs progresses to overt proteinuria as glomerular function deteriorates and eventually results in end-stage renal failure.
  • Diabetic nephropathy is the leading cause of death and disability in diabetes with 35% of type 1 diabetics and 15-60% of type 2 diabetics developing end-stage kidney disease. It is the major cause of end-stage renal disease.
  • the present invention is also directed to preventing and/or treating complications of diabetes associated with changes in blood vessel function, including diabetic nephropathy.
  • Diabetic neuropathy is a complication that affects approximately 50% of individuals with diabetes, it can manifest as a mono- or poly-neuropathy and is associated with significant morbidity.
  • Peripheral neuropathy presents with varying degrees of numbness, paresthesia, hyperesthesia and severe neuropathic pain. Loss of peripheral sensation is often associated with impaired peripheral vascular function which contributes to the development of non-healing ulcers and the potential risk of limb amputation.
  • Autonomic neuropathy can result in gastrointestinal dysfunction, orthostatic hypotension, syncope, bladder dysfunction and impotence.
  • Neuronal damage is due to direct hyperglycaemic-induced damage to nerve parenchyma. Hyperglycemia-induced endothelial changes in the rni crovessels contribute to neuronal ischemia and damage.
  • the present invention contemplates preventing and/or treating complications of diabetes associated with neuropathy.
  • Diabetic retinopathy is a complication of diabetes and is the leading cause of blindness with the prevalence of retinopathy increasing with the duration of diabetes. 80%-90% of diabetics will have some evidence of retinopathy after 20 years of the disease with 30-40% having proliferative retinopathy. Blood vessel damage occurs due to hyperglycemia induced metabolic and chemical changes. Background retinopathy is characterised by capillary vasodilation, increased permeability, and capillary occlusion resulting in retinal ischemia. Neutrophils in diabetics are also less deformable than those in non-diabetics and neutrophils entering the microvessels become trapped in the vessels and adhere to the endothelium of choroidal and retinal capillaries.
  • TMs contributes to retinal vasculature injury by increasing capillary dropout and blood vessel occlusion.
  • Microaneurysms, retinal haemorrhages and exudates are also seen.
  • Proliferative retinopathy results from hypoxia which stimulates endothelial cell migration and proliferation. These new vessels are fragile and frequently rupture; causing retinal haemorrhages that can lead to scarring, retinal detachment and blindness.
  • Macular oedema due to the increase in vascular permeability contributes to the loss of visual acuity.
  • Hie present invention also contemplates preventing and/or treating complications of diabetes associated with retinopathy.
  • the pathogenic effects of hyperglycemia are mediated by at least protein kinase C (PKC) and nuclear factor kappa B (NFKB) in tissues at risk of developing diabetic complications.
  • PKC protein kinase C
  • NFKB nuclear factor kappa B
  • Hyperglycemia results in activation of the polyol pathway. Hie subsequent increase in the NADH/NAD+ ratio increases free radical formation and DAG synthesis. Auto-oxidation of excess glucose and non-enzymatic glyeation results in oxidative cellular damage.
  • These pathways have a complex interaction which results in the activation of PKC through DAC and reactive oxygen species, and of NFKB through AGE and reactive oxygen species.
  • PKC mediates the action of glucose in the glomeruli, retina, aorta and heart of diabetic animals and cultured cells.
  • PKC a, ⁇ l, ⁇ ll and ⁇ have been shown to be activated by high glucose conditions in bovine retinal endothelial cells, PKC a, ⁇ , and ⁇ in the rat retina, and PKC a and ⁇ in rat mesangial cells, and PKC ⁇ l I in rat aorta.
  • Endothelin-1 is a potent vasoconstrictor which has been implicated in causing a reduction in blood flow in the early diabetic eye.
  • the resultant hypoxia stimulates the production of vascular endothelial growth factor (VEGF) which increases vascular permeability and endothelial cell proliferation and migration. This ultimately leads to retinal neovascularisation.
  • VEGF vascular endothelial growth factor
  • Hyperglycemia and Advanced Glyeation Endproducts may also upregulate the expression of adhesion molecules such as ICAM-I (intercellular adhesion molecule), VCAM-1 (vascular cell adhesion molecule) and E-selectin and this is believed to play significant roles in increasing the adhesiveness of the endothelium and be associated with complications of diabetes.
  • adhesion molecules such as ICAM-I (intercellular adhesion molecule), VCAM-1 (vascular cell adhesion molecule) and E-selectin and this is believed to play significant roles in increasing the adhesiveness of the endothelium and be associated with complications of diabetes.
  • method of the present invention is for preventing and/or treating atherosclerosis in a subject.
  • atherosclerosis in a mouse model of atherosclerosis, treatment with a polyunsaturated fatty acid compound was found to reduce plaque area.
  • the method of the present invention provides a method for preventing and/or treating undesired or uncontrolled angiogenesis including, for example, tumour induced angiogenesis.
  • the present invention contemplates the administration of a compound, salt or solvate thereof to a subject, wherein the compound is selected from the group consisting of: (i) a polyunsaturated fatty acid including an oxa and/or thia substitution at either or both of the ⁇ or ⁇ position of the polyunsaturated fatty acid; (ii) a polyunsaturated fatty acid eovalently coupled to an amino acid; (iii) a polyunsaturated nitroalkene or nitroalkyne; (iv) a n-3 polyunsaturated fatty acid; and (v) a n-6 polyunsaturated fatty acid.
  • polyunsaturated as used throughout the specification is to be understood to mean a molecule including a carbon chain which contains more than one double and/or triple valence bond.
  • the term includes within its scope geometric isomers.
  • polyunsaturated fatty acid as used throughout the specification is to be understood to mean a carboxylic acid, or a salt thereof, the carboxylic acid including a carbon chain of which contains more than one double and/or triple valence bond.
  • a compound may be both a polyunsaturated fatty acid including an oxa and/or thia substitution at either or both of the ⁇ or ⁇ position of the polyunsaturated fatty acid and an n-3 polyunsaturated fatty acid or an n-6 polyunsaturated fatty acid.
  • the compound, salt or solvate thereof includes a carbon chain containing 16 to 26 carbon atoms.
  • the compound, salt or solvate thereof may have 1 to 6 carbon double bonds,, including 1, 2, 3, 4, 5 or 6 carbon double bonds. In some embodiments, the compound, salt or solvate thereof may have between 3 and 6 carbon double bonds.
  • the compound has an polyunsaturated hydrocarbon chain having 18 to 26 carbon atoms and three double bonds separated by methylene groups, with the first double bond relative to the omega carbon atom being between the third and fourth or sixth and seventh carbon atoms.
  • the compound includes a polyunsaturated fatty acid including an oxa substitution at the ⁇ position of the polyunsaturated fatty acid.
  • Examples of ⁇ -oxa compounds include ⁇ -oxa-23:4n-6; ⁇ -oxa-21:3n-6; ⁇ -oxa-21:3n-3; ⁇ - oxa-25:6n-6; ⁇ -oxa-21:4n-3; 16-OH- ⁇ -oxa-21:3n-6; 16-OH- ⁇ -oxa-21:3n-3; ⁇ -oxa-18:3n-3, ⁇ -oxa-20:4n-6, ⁇ -oxa-20:5n-3, ⁇ -oxa-22:6n-3, ⁇ -oxa-23:4n-6, 15-OOH- ⁇ -oxa-20:4n-6, ⁇ - oxa-23:4n- ⁇ , ⁇ -oxa-21:3n-6, ⁇ oxa ⁇ 21 :3n ⁇ 3 . , ⁇ -oxa-25:6n-3, ⁇ -oxa-21:4n-3, 16-OH- ⁇ -o
  • the compound includes a n-3 polyunsaturated fatty acid. In some embodiments, the compound is ⁇ -oxa 21:3 n-3. ⁇ -oxa 21:3 n-3 is also referred to herein as "MP5".
  • the compound includes a n-6 polyunsaturated fatty add.
  • the compound is compound is ⁇ -oxa 23:4 n-6.
  • ⁇ -oxa 23:4 n-6 is also referred to herein as "MP3".
  • lhe compound includes a polyunsaturated fatty acid including a lhia substitution at the ⁇ position of the polyunsaturated fatty acid. Examples of ⁇ - thia compounds include ⁇ -thia-21:3n-6; ⁇ -thia-21:3n-3; ⁇ -thia-25:6n-3; ⁇ -thia-23:4n-6; ⁇ - i arboxymethyl- ⁇ -thia-23:4n-6.
  • the compound includes a polyunsaturated fatty acid including a thia substitution at the ⁇ position of the polyunsaturated tatty acid.
  • a polyunsaturated fatty acid including a thia substitution at the ⁇ position of the polyunsaturated tatty acid.
  • Examples ot ⁇ -ihia polyunsaturated fatty adds include ⁇ -thia-22:3n-6; ⁇ -thia-22:3n-3; ⁇ -lhia-24:4n-fo; ⁇ -thia- 25:6n-3.
  • the method of the present invention also specifically contemplates administering a combination ot a n-3 polyunsaturated fatty add as hereinbefore described and a n-6 polyunsaturated fatty add as hereinbefore described for the prevention and/or treatment of the diseases, conditions and states dest ribed herein.
  • the compound may also include a polyunsaturated fatty acid covalently coupled to an amino acid.
  • the amino acid may be a natural amino acid, or an amino add sequences modified either by natural processes, such as post- lranslational processing, or by a chemical modification technique known in the art.
  • Naturally o ⁇ urring amino add include alanine, arginine, asparagine, aspartu acid, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, glycine, histidine, isoleudne, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, and valine, in some embodiments, the amino acid is glycine or aspartic acid.
  • the polyunsaturated fatty acid may be coupled to the amino acid by way of an amide linkage, although it will be appreciated that the amino acid may be coupled to carboxylic by other means known in the art. Such compounds are generally described in US patent 5,998,476.
  • the amino add conjugated compound may be ⁇ -lin ⁇ lenic acid- glycine, ⁇ -linolenic add-glydne, arachidonic add-glycine, docosahexaenoic add- glydne, eicosapentaenoic glycine, ⁇ -linolenic add-aspartic acid, ⁇ -linolenic acid- aspartic add, arachidonic add-aspartic acid, eicosapentaenoic add-aspartic acid and docosahexaenoic add-aspartic acid.
  • the compound,, salt or solvate thereof may be a polyunsaturated nitroaikene or nitroalkyne.
  • the term ''polyunsaturated nitroalkene or nitroalkyne as used throughout the specification is to be understood to mean an alkene or alkyne including a nitro group, the molecule including a carbon chain of which contains more than one double and/or triple valence bond.
  • the polyunsaturated nitroalkene or nitroalkyne may have the formula X- NO2, wherein X is a polyunsaturated hydrocarbon chain of 14 to 26 carbon atoms, and which may be optionally substituted.
  • the polyunsaturated nitroalkene or nitroalkyne has a formula of Ri-X-NO:, wherein X is an polyunsaturated hydrocarbon chain of 14 to 26 carbon atoms, and which may be optionally substituted, and Ri is (CH2),-.(COOH) m , in which n is 0 to 2, and m is independently 0 to 2.
  • Ri is (CH2),-.(COOH) m , in which n is 0 to 2, and m is independently 0 to 2.
  • X is a hydrocarbon chain of 18 to 22 carbon atoms, and in one specific embodiment has 3-6 double bonds.
  • the polyunsaturated nitroaikene or nitroalkyne is selected from the group consisting of (z,z,,z)-l-Nitro-9,12,15-octadecatriene, (z,z,z)-l-Nitro-6,9,12- octadecatriene, (ali-z)-l-Nitr ⁇ -5,8,ll,14-eico-satetraene, (ali-z)-l-Nitro-4,7,10,13,16,19- docosahexaene, (all-Z)-4-Nitrotricosa-8J 1,14,17-tetraenoic acid, 3-[ ⁇ all-Z)-Nonadeca- 4,7,10, i3-tetrae ⁇ l]-3-nitropentane-1,5-dicarboxylk: acid.
  • substituted means that a hydrogen atom on a molecule has been replaced with a different atom or molecule.
  • the atom or molecule replacing the hydrogen atom is denoted as a "substituent".
  • substituted specifically envisions and allows for substitutions that are common in the art. However, it is generally understood by those skilled in the art that the substituents should be selected so as to not adversely affect the pharmacological characteristics of the compound or adversely interfere with the use of the medicament.
  • alkyl as used throughout the specification is to be understood to mean a group or part of a group of saturated straight chain, branched or cyclic hydrocarbon groups, such as a Ct-C-* alkyl, a C1-C30 alkyl, or a Ct-Cr alkyl.
  • straight chain and branched alkyl examples include methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyi, n-pentyl and branched isomers thereof, n-hexyl and branched isomers thereof, n-heptyl and branched isomers thereof, n-octyl and branched isomers thereof, n-nonyl and branched isomers thereof, and n-decyl and branched isomers thereof.
  • cyclic alkyl examples include mono-or polycyclic alkyl groups such as cydopropyl, cydobutyl, cydopentyl, cydohexyl, cydoheptyl, cyclooctyl, cyciononyl, cydodecyl, and the like.
  • An aikyi group may be further optionally substituted by one or more optional substituents as herein defined.
  • alkenyl as used throughout the specification is to he understood to mean a group or part of a group straight chain . , branched or cyclic hydrocarbon residues containing at least one carbon to carbon double bond including ethyienically monounsaturated or polyunsaturated alkyl or cycloaikyl groups.
  • alkenyl include vinyl, allyl, 1 -methyl vinyl, butenyl, iso-butenyl, 3-methyl-2-butenyL 1- pentenyl, cydopentenyl, 1-methyl-cydopentenyl, 1-hexenyl, 3-hexenyl,.
  • alkenyl group may be optionally substituted by one or more optional substituents as herein defined.
  • alkynyl as a group or part of a group as used throughout the specification is to be understood to mean straight chain, branched or cyclic hydrocarbon residues containing at least one carbon-carbon triple bond including ethynicaUy mono-, cli-or polyunsaturated alkyl or cycloaikyl groups as previously defined. Examples include ethynyl, 1- propynyl, 2-propynyl, burynyl isomers, pentynyl isomers, and the like. An alkynyl group may be further optionally substituted by one or more optional substituents as herein defined.
  • heteroatom as a group or part of a group as used throughout the specification is to be understood to mean monocyclic, poly cyclic, fused or conjugated hydrocarbon residues wherein one or more carbon atoms (and where appropriate, hydrogen atoms attached thereto) are replaced by a heteroatom so as to provide a non- aromatic residue.
  • Suitable heteroatoms include nitrogen, oxygen, sulphur and selenium. Where two or more carbon atoms are replaced, this may be by two or more of the same heteroatom or by different heteroatoms.
  • heterocyclic groups include pyrrolidinyl, pyrrolinyl, piperidyl, piperazinyl, morpholino, indolinyl, imiazolidinyl, pyrazolidinyl, thiomorpholino, dioxanyl, tetrahydrofuranyl, tetrahydropyranyl, tctrahydropyrrolyl, and the like.
  • a heterocydyl group may be further optionally substituted by one or more optional suhstituents as herein defined.
  • aryl as a group or part of a group as used throughout the specification is to be understood to mean: (i) an optionally substituted monocyclic, or fused polycyciic, aromatic carbocycle (ring structure having ring atoms that are all carbon) preferably having from 5 to 12 atoms per ring.
  • aryl groups include phenyl, naphthyl, and the like; and (ii) an optionally substituted partially saturated bi cyclic aromatic carbocyclic moiety in which a phenyl and a Cs-7 cycloalkyl or C?-7 cycJoalkenyl group are fused together to form a cyclic structure, such as fetrahydronaphthyi, indenyi or indanyl.
  • heteroaryl as a group or part of a group as used throughout the specification is to be understood to mean an optionally substituted aromatic ring having one or more heteroatoms as ring atoms in the aromatic ring with the remainder of the ring atoms being carbon atoms.
  • Suitable heteroatoms include nitrogen, oxygen, sulphur and selenium.
  • heteroaryl examples include thiophene, benzothiophene, benzofuran, benzimidazole, benzoxazole, benzofhiazole, benzisothiazole, naphtho[2,3- bjthiophene, furan, isoindolizine, xantholene, phenoxatine, pyrrole, imidazole, pyrazole, pyridine, pyrazine, pyrimidine, triazine, tetrazole, pyridazine, indole, isoindole, IH-indazoie, purine, quinoline, isoquinoline, phthalazine, naphthyridine, quinoxaline, cinnoline, carbazole, phenanthridine, acridine, phenazine, thiazole, isothiazole, phenothiazine, oxazole, isooxazole
  • acyl as a group or part of a group as used throughout the specification is to be understood to mean a group containing the moiety OO (and not being a earboxylic acid, ester or amide).
  • examples of acyl include forrnyl; straight chain or branched alkanoyl such as, acetyl, propanoyl, bulanoyl, 2-methylpropanoyl, pentanoyl, 2,2- dimelhylpropanoyl, hexanoyl, heplanoyl.
  • odanoyl nonanoyl, decanoyl, undecanoyl, dodecanoyl, tridecanoyl, fetradecanoyl, pentadecanoyl, hexadecanoyf, heptadecanoyl, ⁇ i tadecanoyl, nonadecanoyl and icosanoyl; cycloalkylcarbonyl such a « cyclopropylcarbonyl cydobutylcarbony], cyclopentylcarbonyl and cyclohexykarbonyl; aroyl sudi as benzoyl, ioluoyl and naphlhoyl; aralkanoyl such as phenylalkanoyl (e.
  • phenyiacefyl phenylpropanoyl, phenylbulanoyl, phenylisobutylyl, phenylpentanoyl and phcnylhexanoyl
  • naphlhylalkanoyl e g naphlhylacetyl. naphthylpropanoyl and naphthylbutanoyl]
  • aralki-noyl suth as phenylalkenoyl c. g.
  • phenylpropenoyl phenylb ⁇ tenoyl
  • phenylmethacryloyl phenylmethacryloyl
  • pheriylpentenoyl phenylhexenoyl and naphthylalkenoyl
  • aryloxy alkanoyl such as phenoxyacelyl and phenovypropionyl
  • arylthiocarbamoyl such as phenyllhiocarbamoyl
  • arylglyoxyloyl such as phenylglyoxyloyl and naphthylglyoxyloyl
  • aryfculfonyl such as phonylsulfonyl and napthylsulfonyl
  • hcttToi yclicalkanoyl such a « tliienylacetyl, thienylprcpanoyl, thienylbutanoyl, thienylpentanoyl, thienylhexancyl, thiazolyl acet
  • alkoxy, alkenoxy aryloxy, heteroaryloxy, heterocyclyloxy and acyloxy respectively denote alkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocyclyl and acyl groups as hereinbefore defined when linked by oxygen,
  • thioalkyl refers to an alkyl group when linked by sulfur.
  • carboxyl as a group or part of a group refers generally to the group COiH and "carboxyl ester” as a group or part ot a group refers generally to the group CO2R wherein R is any group not being ⁇ I.
  • amino as a group or part of a group as used throughout the specification is to be understood to mean the group NRR' and "amido” as a group or part of a group refers generally to the group CONRR', wherein R and R' can independently be H, alkyl, alkenyl, alkynyi, aryl, acyl, heteroaryl, heteroeytiyl, or derivatives thereof.
  • ''halo as used throughout the specification is to be understood to mean a halogen group, including fiuoro, chloro, bromo and iodo groups.
  • the compound includes one or more substitutions selected from the group consisting of a hydroxy!, a hydroperoxy, a peroxy, and a carboxyalkyl substitution.
  • the compound, salt or solvate thereof may also be in the form of a pro-drug.
  • pro-drug as used throughout the specification is to be understood to mean a precursor which upon administration to a biological system, undergoes chemical conversion by metabolic or chemical processes to yield the compound, salt or solvate thereof.
  • the method of the present invention contemplates administration of the compound, salt or solvate thereof to a subject.
  • the compound,, salt or solvate thereof may be delivered to the desired site of action directly, or be delivered by administration of the compound, salt or solvate thereof to the subject.
  • Administration and delivery of the compound, salt or solvate thereof may be, for example, by intravenous, intraperitoneal, subcutaneous, intramuscular, oral, or topical route, or by direct injection into the desired site of action.
  • the mode and route of administration in most cases will depend on the type of disease, condition or state being treated.
  • the effective amount of the compound, salt or solvate thereof to be delivered is not particularly limited, so long as it is within such an amount and in such a form that generally exhibits a useful or therapeutic effect.
  • the term "effective amount" is the quantity which when delivered or administered, improves the prognosis of the subject.
  • the amount to be delivered will depend on the particular characteristics of the condition being treated, the mode of delivery, and the characteristics of the subject, such as general health, other diseases,, age, sex, genotype, body weight and tolerance to drugs. A person skilled in the art will be able to determine appropriate dosages depending on these and other factors.
  • the administration of the compound, salt or solvate thereof to the subject includes recurrent administration of the compound, salt or solvate thereof to the subject daily.
  • the treatment regime may occur daily over a period of 12 weeks.
  • effective amounts of the compound, salt or solvate thereof typically range between about 0.1 mg/kg body weight per day and about 1000 mg/kg body weight per day, and in some embodiments between 1 mg/kg body weight per day and 100 mg/kg body weight per clay.
  • the administration of the compound, salt or solvate thereof may also include the use of one or more pharmaceutically acceptable additives, including pharmaceutically acceptable salts, amino acids, polypeptides, polymers, solvents, buffers, excipients, preservatives and bulking agents, taking into consideration the particular physical, microbiological and chemical characteristics of the compound to be administered.
  • pharmaceutically acceptable additives including pharmaceutically acceptable salts, amino acids, polypeptides, polymers, solvents, buffers, excipients, preservatives and bulking agents, taking into consideration the particular physical, microbiological and chemical characteristics of the compound to be administered.
  • the method of the present invention may further include administering to the subject an Angiotensin-Converting Enzyme (ACE) inhibitor.
  • ACE Angiotensin-Converting Enzyme
  • the ACE inhibitor may be selected from one or more of the group consisting of (i) a sulfhydryl-containing ACE inhibitor, including Captopril; (ii) a dicarboxylate- containing ACE inhibitors, Enalapril, Ramipril, Quinapril, Perindopril, Lisinopril, and Benazepril; and (iii) a phosphonate-containing ACE inhibitor, including Fosinopril.
  • ACE-inhibitors are generally as described in "ACE Inhibitors” (2001) ed. by P,D. Louis-Juste and G.E. Plante, Birkhauser Verlag.
  • the present invention provides the use of one or more compounds, or salts or solvates thereof, in the preparation of a medicament for preventing and/or treating one or more of (i) diabetes, or a complication thereof; (ii) ischemia/reperfusion injury, and complications thereof; (iii) atherosclerosis; (iv) restenosis; (v) tumour growth; and (vi) un desired or uncontrolled angiogenesis in a subject; the compound being selected from the group consisting of (i) a polyunsaturated fatty acid including an oxa and/or thia substitution at either or both of the ⁇ or ⁇ position of the polyunsaturated fatty add; (ii) a polyunsaturated fatty acid covalently coupled to an amino acid; (iii) a polyunsaturated nitroalkene or nitroalkyne; (iv) a n-3 polyunsaturated fatty acid; and (v) a n-6 polyunsaturated fatty
  • the medicament is for preventing and/or treating diabetes and/or a complication thereof as hereinbefore described.
  • preventing/or treating diabetes and/or a complication thereof in a subject includes a reduction in glucose production by the subject.
  • a reduction in glucose production by the subject may include a reduction in gluconeogensis in the subject, as hereinbefore described.
  • the medicament is for preventing and/or treating atherosclerosis in a subject as hereinbefore described.
  • the compound, salt or solvate thereof used in the preparation of the medicament may be a compound, salt or solvate thereof, as hereinbefore described.
  • the use may further include the use of an Angiotensin- Converting Enzyme (ACE) inhibitor, as hereinbefore described, in the preparation of the medicament.
  • ACE Angiotensin- Converting Enzyme
  • the medicament may take the form of a pharmaceutical composition.
  • the pharmaceutical composition may include the compound, salt or solvate thereof together with an ACE inhibitor as hereinbefore described.
  • the present invention provides a pharmaceutical composition including an ACE inhibitor and a compound, or a salt or solvate thereof, selected from the group consisting of (i) a polyunsaturated fatty acid including an oxa and/or thia substitution at either or both of the ⁇ or ⁇ position of the polyunsaturated fatty acid; (ii) a polyunsaturated fatty acid covalently coupled to an amino acid; (iii) a polyunsaturated nitroalkenc or nitroalkyne; (iv) a n-3 polyunsaturated fatty acid; and (v) a n-6 polyunsaturated fatty acid.
  • a pharmaceutical composition including an ACE inhibitor and a compound, or a salt or solvate thereof, selected from the group consisting of (i) a polyunsaturated fatty acid including an oxa and/or thia substitution at either or both of the ⁇ or ⁇ position of the polyunsaturated fatty acid; (ii)
  • the ACE inhibitor used in the pharmaceutical composition may be an ACE inhibitor as hereinbefore described.
  • the compound or a salt or solvate thereof, used in the pharmaceutical composition may be as hereinbefore described.
  • the pharmaceutical composition may be formulated into a composition that is suitable for the desired route and mode of delivery or administration.
  • an active agent may be admixed with a pharmaceutically acceptable carrier, diluent, excipient,. suspending agent, lubricating agent, adjuvant, vehicle, delivery system, emulsifier, disintegrant, absorbent, preservative, surfactant, colorant, giidant, anti-adherent, binder, flavourant or sweetener.
  • a pharmaceutical carrier can be any compatible nontoxic substance suitable for delivery of the agent to a subject.
  • Examples of pharmaceutically acceptable additives include pharmaceutically acceptable salts, amino acids, polypeptides, polymers, solvents, buffers, excipients, preservatives and bulking agents, taking into consideration the particular physical, microbiological and chemical characteristics of the compound to be administered.
  • the active compound can be prepared into a variety of pharmaceutical acceptable compositions in the form of, e.g., an aqueous solution, an oily preparation, a fatty emulsion, an emulsion, a lyophilised powder for reconstitute on, etc. and can be administered as a sterile and pyrogen free intramuscular or subcutaneous injection or as injection to an organ, or as an embedded preparation or as a transmucosal preparation through nasal cavity, rectum, uterus, vagina, lung, etc.
  • the composition may be administered in the form of oral preparations (for example solid preparations such as tablets, caplets, capsules, granules or powders; liquid preparations such as syrup, emulsions, dispersions or suspensions).
  • compositions containing the compound, salt or solvate thereof may also contain one or more of a pharmaceutically acceptable preservative,, buffering agent, diluent, stabiliser, chelating agent, viscosity-enhancing agent, dispersing agent, pH controller, solubility modifying agent or isotonic agent.
  • a pharmaceutically acceptable preservative such as benzoic acid esters of para- hydroxybenzoic acid, propylene glycol, phenols, phenylethyl alchohol or benzyl alcohol.
  • suitable buffers are sodium phosphate salts, citric acid, tartaric acid and the like.
  • suitable stabilisers include antioxidants such as alpha- tocophero!
  • suitable viscosity enhancing agents, suspending or dispersing agents are substituted cellulose ethers, substituted cellulose esters, polyvinyl alcohol, polyvinylpyrrolidone, polyethylene glycols, carbomer, polyoxypropylene glycols, sorbitan monooleate, sorbitan sesquioleate, poly oxy ethylene hydrogenated castor oil 60.
  • suitable pH controllers include hydrochloric acid, sodium hydroxide, buffers and the like.
  • suitable isotonic agents are glucose, D-sorbitol or D- mannitol, sodium chloride.
  • composition may be administered orally, parenterally, by inhalation spray, adsorption, absorption, topically, rectally, nasally, bucally, vaginally, intraventricularly, via an implanted reservoir in dosage formulations containing conventional non-toxic pharrnace ⁇ ticaUy-acceptable carriers, or by any other convenient dosage form.
  • parenteral as used herein includes subcutaneous, intravenous, intramuscular, intraperitoneal, intrathecal, intraventricular, intrasternal, and intracranial injection or infusion techniques.
  • the composition When administered parenterally, the composition will normally be in a unit dosage, sterile, pyrogen free injectable form (solution, suspension or emulsion, which may have been reconstituted prior to use) which is usually isotonic with the blood of the recipient with a pharmaceutically acceptable carrier.
  • sterile injectable forms are sterile injectable aqueous or oleaginous suspensions. These suspensions may be formulated according to techniques known in the art using suitable vehicles, dispersing or wetting agents and suspending agents.
  • the sterile injectable forms may also be sterile injectable solutions or suspensions in non-toxic parentcrally acceptable diluents or solvents, for example, as solutions in 1,3-butanediol.
  • Suitable vehicles and solvents that may be employed are water,. ethanol, glycerol, saline, Ringer's solution, dextrose solution, isotonic sodium chloride solution, and Hanks' solution.
  • sterile, fixed oils are conventionally employed as solvents or suspending mediums.
  • any bland fixed oil may be employed including synthetic mono- or d ⁇ -glycerkles, corn, cottonseed, peanut, and sesame oil.
  • Fatty acids such as ethyl oleate, isopropyl rnyristate, and oleic acid and its glyceride derivatives, including olive oil and castor oil, especially in their poiyoxyethylated versions, are useful in the preparation of injectables.
  • These oil solutions or suspensions may also contain long-chain alcohol diluents or dispersants.
  • the carrier may contain minor amounts of additives, such as substances that enhance solubility, isotonicity, and chemical stability, for example antioxidants, buffers and preservatives,
  • composition may be in a form to be reconstituted prior to administration.
  • examples include lyophilization, spray drying and the like to produce a suitable solid form for reconstitute on with a pharmaceutically acceptable solvent prior to administration.
  • Compositions may include one or more buffer, bulking agent,, isotonic agent and cryoprotectant and lyoprotectant.
  • excipients include, phosphate salts, citric add, non-reducing sugars such as sucrose or trehalose, polyhydroxy alcohols, amino acids, methyl amines, and lyotropic salts are preferred to the reducing sugars such as maltose or lactose.
  • the composition may be suitable for oral administration.
  • suitable oral formulations may include unit dosage forms such as tablets, caplets, cachets, powder, granules, beads, che oddse lozenges, capsules, liquids, aqueous suspensions or solutions, or similar dosage forms, using conventional equipment and techniques known in the art.
  • Such formulations typically include a solid, semisolid, or liquid carrier.
  • Exemplary carriers include excipients such as lactose, dextrose, sucrose, sorbitol, manrutol, starches, gum acacia, calcium phosphate, mineral oil, cocoa butter, oil of theobroma, alginates, tragacanth, gelatin, syrup, substituted cellulose ethers, polyoxyethylene sorbitan monoiaurafe, methyl hydroxybenzoate, propyl hydroxybenzoate, talc, magnesium s tear ate, and the like.
  • a tablet may be made by compressing or moulding optionally with one or more accessory ingredients.
  • Compressed tablets may be prepared by compressing, in a suitable machine, the active ingredient in a free-flowing form such as a powder or granules, optionally mixed with a binder, lubricant, inert diluent, surface active, or dispersing agent.
  • Moulded tablets may be made by moulding in a suitable machine, a mixture of the powdered active ingredient and a suitable carrier moistened with an inert liquid diluent.
  • compositions may also be a sustained release composition.
  • Such compositions may be formulated with additional components such as vegetable oil (for example soybean oil, sesame oil, camellia oil, castor oil, peanut oil, rape seed oil); middle fatty acid triglycerides; fatty add esters such as ethyl oleate; polysiloxane derivatives; alternatively, water-soluble high molecular weight compounds such as hyaluronic acid or salts thereof (weight average molecular weight: ca. 80,000 to 2,,000,,00O), carboxymethylcelluiose sodium (weight average molecular weight: ca.
  • hydroxypropylcellulose viscosity in 2% aqueous solution: 3 to 4,000 cps
  • atherocollagen weight average molecular weight: ca. 300,000
  • polyethylene glycol weight average molecular weight: ca. 400 to 20,000
  • polyethylene oxide weight average molecular weight: ca. 100,000 to 9,000,000
  • hydroxypropylmethylcellulose viscosity in 1% aqueous solution: 4 to 100,000 cSt
  • methylcellulose viscosity in 2% aqueous solution: 15 to 8,000 cSt
  • polyvinyl alcohol viscosity: 2 to 100 cSt
  • polyvinylpyrrolidone weight average molecular weight: 25,000 to 1,200,000.
  • the sustained release composition may include, for example, a hydrophobic polymer matrix or biodegradable polymer for controlled release of the active over a period of days.
  • Such compositions may be moulded into a solid implant, or externally applied patch, suitable for providing efficacious concentrations of the active over a prolonged period of time without the need for frequent re-dosing.
  • sustained release films are well known to the art.
  • Other examples of polymers commonly employed for this purpose that may be used include nondegradabie ethylene-vinyl acetate copolymer a degradable lactic acki-glycolic acid copolymers which may be used externally or internally.
  • Certain hydrogels such as poly(hydroxyerhy]methacrylate) or poiy(vinylalcohol) also may be useful, but for shorter release cycles than the other polymer release systems, such as those mentioned above.
  • the present invention also contemplates topical pharmaceutical formulations.
  • the composition may be in the form of a solution, spray, lotion, cream (for example a non-ionic cream), gel, paste or ointment.
  • the composition may be delivered via a liposome, nanosome, ribosome, or nutri-diffuser vehicle.
  • the compound, salt or solvate thereof and the ACE inhibitor may also be produced in a combination product.
  • the present invention provides a combination product including the following components: an ACE inhibitor; and a compound, salt or solvate thereof selected from the group consisting of: (i) a polyunsaturated fatty acid including an oxa and/or thia substitution at either or both of the ⁇ or ⁇ position of the polyunsaturated fatty acid; (ii) a polyunsaturated fatty acid covalently coupled to an amino acid; (iii) a polyunsaturated nitroalkene or nitroalkyne; (W) a n-3 polyunsaturated fatty acid; and (v) a n-6 polyunsaturated fatty add; wherein the components are provided in a form for separate administration to a subject,, or in a form for co-administration to a subject.
  • the subject is susceptible to, or suffering from a PKC- ⁇ mediated disease,, condition or state, or a disease, condition or state that would benefit from inhibition of activation of PKC- ⁇ .
  • the subject is susceptible to, or suffering from an NFKB mediated disease, condition or state in a subject, or a disease, condition or state that would benefit from inhibition of activation of NFKB mediated disease, condition or state.
  • the present invention also provides a combination product including the following components: a n-3 polyunsaturated fatty acid; and an n-6 polyunsaturated fatty acid; wherein the components are provided in a form for separate administration to a subject, or in a form for co-administration to a subject.
  • the subject is susceptible to, or suffering from a disease, condition or state selected from one or more of the group consisting of (i) diabetes, or a complication thereof, including diabetic microvascular complications and/or diabetic macrovascular complications, diabetic retinopathy, diabetic nephropathy and diabetic uremia; (ii) ischemia/reperf usion injury, and complications thereof; (iii) atherosclerosis;
  • the components of the combination product may packaged separately or together in suitably sterilized containers such as ampoules, bottles, or vials, either in multi-dose or in unit dosage forms.
  • the containers are typically hermetically sealed. Methods are known in the art for the packaging of the components.
  • the present invention also provides screening assays lor identity ing polyunsaturated fatty adds that may be used as inhibitors of PkC - ⁇ activation, and lor identifying polyunsaturated fatty acids that are therapeutic i andidates for PKC- ⁇ mediated diseases, condition and states, and thus can be used in the preparation of a medicament for the prevention and/or treatment of such diseases, states or conditions.
  • the present invention also provides a method of identifying an inhibitor of activation of a PkC- ⁇ enzyme, the method ⁇ u hading: providing a test compound, or a salt or solvate thereof, selected from the group consisting of (i) a polyunsaturated fatty acid including an o ⁇ a and/or thia substitution at either or both of the ⁇ or ⁇ position of the polyunsaturated fatty acid; (ii) a polyunsaturated tally acid covalenlly coupled to an amino acid; (iii) a polyunsaturated nitr ⁇ alkene or nitroalkyne; (iv) a n-3 polyunsaturated fatty add; and (v) a n-6 polyunsaturated fatty acid; determining the ability of the test compound to inhibit translocation of a PkC- ⁇ enzyme from the cytoplasm to the particulate fraction in a cell; and identifying the test compound as an inhibitor ol activation ol a P
  • Determination that a test compound inhibits translocation of a PkC- ⁇ enzyme from the cytoplasm to a particulate fraction may be achieved by a suitable method known in the art.
  • selection of a suitable compound, salt or solvate lhereol for inhibiting activation of a PKC" enzyme may be achieved by determining the ability ot a seleded compound, salt or solvate thereof to inhibit activation of a PkC enzyme.
  • the ability of a selected compound, salt or solvate thereof to inhibit translocation of a PKC enzyme from the cytoplasm Io a particulate fraction will be indicative thai the compound, salt or solvate thereof may be used in the present invention.
  • the method of identification may utilise a cell in a cell-free in vitro system, a cell present in a cell in in vitro culture, or a cell present in a biological system, such as a subject.
  • the present invention may also be used to identify an agent for preventing and/or treating a PKC- ⁇ mediated disease, condition or state.
  • the present invention also provides screening assays for identifying polyunsaturated fatty acids that may be used as inhibitors of NF ⁇ : ⁇ activation.
  • the present invention also provides a method of identifying an inhibitor of activation of a NF ⁇ " ⁇ enzyme, the method including: providing a test compound, or a salt or solvate thereof, selected from the group consisting of (i) a polyunsaturated fatty add including an oxa and/or thia substitution at either or both of the ⁇ or ⁇ position of the polyunsaturated fatty acid; (ii) a polyunsaturated fatty acid covalently coupled to an amino acid; (iii) a polyunsaturated nitroalkene or nitroaikyne; (iv) a n-3 polyunsaturated fatty acid; and (v) a n-6 polyunsaturated fatty acid; determining the ability of the test compound to inhibit activation of a NF K ⁇ enzyme; and identifying the test compound as an inhibitor of activation of a NFic ⁇ enzyme.
  • a test compound or a salt or solvate thereof, selected from the group consisting of (i
  • test compound inhibits activation of NFx ⁇ may be achieved by a suitable method known in the art.
  • selection of a suitable compound, salt or solvate thereof may be achieved by determining the ability of a selected compound, salt or solvate thereof to inhibit activation of NFKB.
  • the method of identification may utilise a cell in a cell-free in vitro system, a cell present in a cell in in vitro culture, or a cell present in a biological system, such as a subject.
  • High Throughput screening methods are as described in High Throughput Screening (Humana Press Inc. edited by William P. ⁇ anzen, 2002).
  • the method of identification may utilise a cell in a cell-free in vitro system, a cell present in a cell in in viho culture, or a cell present in a biological system, such as a subject.
  • the present invention may also be used to identify an agent for preventing and/or treating a NF K ⁇ mediated disease, condition or state.
  • the present invention also contemplates an agent identified according to the above methods.
  • Figure ' ! shows monolayer of bovine retinal endothelial cells prepared by primary cell culture at the 4 th passage.
  • Figure 2 shows fluorescent antibody staining with Von Willebrand Factor antibody. Endothelial cells were shown to be >95% pure.
  • Figure 3 shows expression of PKC isozymes in bovine retinal endothelial cells (BREC).
  • BRECs were grown to confluence (3 x IQ" cells) in tissue culture plates and sonicated in buffer containing 2% Triton-XIOO to extract PKC from the particulate fraction of the cells.
  • the presence of PKC isozymes in BREC was analysed by Western blotting and stained with antibodies for PKC a, (31, ⁇ ll, ⁇ and ⁇ . Representative bands derived from
  • FIG. 4 shows expression of PKC isozymes in human umbilical vein endothelial ceils (HUVEC). HUVECs were grown to confluence (3 x 10 6 cells) in tissue culture plates and sonicated in buffer containing 2% Triton-XIOO to extract PKC from the particulate fraction of the cells. The presence of PICC isozymes was analysed by Western blotting and stained with antibodies for PKC a, ⁇ l, ⁇ lT, ⁇ and ⁇ . Representative bands derived from 3 separate experiments are shown.
  • HUVECs human umbilical vein endothelial ceils
  • FIG. 5 shows expression of PKC isozymes in human T lymphocytes.
  • Human T lymphocytes were prepared from healthy donors and adjusted to a concentration of 4 x 10 6 ceils/ml. Cells (1 x 10 7 ) were sonicated and the soluble fractions were analysed for the expression of PKC a, ⁇ l, ⁇ ll, ⁇ , 0 and ⁇ by Western blotting. Representative bands derived from 3 separate experiments are shown.
  • FIG. 6 shows expression of PKC isozymes in HL60 cells.
  • HL60 cells were cultured at a density of ⁇ 1 x 10 r cells/ml.
  • Cells (1 x 10 7 ) were sonicated and soluble fractions were analysed for the presence of PKC ⁇ , ⁇ l, ⁇ ll, ⁇ , 0 and ⁇ by Western blotting. Representative bands derived from 3 separate experiments are shown.
  • FIG 7 shows translocation of PKC a in PMA-acfivated BREC.
  • BREC were grown in tissue culture plates to confluence (1x10 h cells) supplemented with DMEM/plasrna. After incubation with 10OnM PMA for 5 min, cells were sonicated and PKC was extracted from the particulate fraction by sonication in the presence of 2% Triton-XIOO. The amount of PKC ⁇ in the particulate fraction was determined by Western blotting and a representative blot is shown. The densities of the bands were quantified with Image Quant software and are expressed as percentage of control (100%). The data are expressed as mean + SEM derived from 3 separate experiments (*p ⁇ 0.05).
  • FIG 8 shows translocation of PKC ⁇ l in PMA-activated BREC.
  • BREC were grown in tissue culture plates to confluence (1x10 h cells) supplemented with DMEM/plasma. After incubation with 10OnM PMA for 5 min, cells were sonicated and PKC was extracted from the particulate fraction by sonication in the presence of 2% Triton-XIOO. The amount of PKC ⁇ l in the particulate fraction was determined by Western blotting and a representative blot is shown. The densities of the bands were quantified with Image Quant software and are expressed as percentage of control (100%). The data are expressed as mean + SEM derived from 5 separate experiments. ( * p ⁇ 0.01 )
  • FIG. 9 shows translocation of PKC ⁇ in PMA-activated BREC.
  • BREC were grown in tissue culture plates to confluence (IxIO 6 cells) supplemented with DMEM/plasma. After incubation with 10OnM PMA for 5 min, cells were sonicated and PKC was extracted from the particulate fraction by sonication in the presence of 2% Triton-XIOO. The amount of PKC5 in the particulate fraction was determined by Western blotting and a representative blot is shown. The densities of the bands were quantified with Image Quant software and are expressed as percentage of control (100%). The data are expressed as mean + SEM derived from 6 separate experiments.
  • FIG 10 shows translocation of PKC ⁇ in PMA-activated BREC.
  • BREC were grown in tissue culture plates to confluence (IxIO 6 cells) supplemented with DMEM/plasma. After incubation with 10OnM PMA for 5 min, cells were sonicated and PKC was extracted from the particulate fraction by sonication in the presence of 2% Triton-XIOO. The amount of PKO; in the particulate fraction was determined by Western blotting and a representative blot is shown. The densities of the bands were quantified with Image Quant software and are expressed as percentage of control (100%). The data are expressed as mean + SEM derived from 3 separate experiments.
  • FIG 11 shows effect of Wgh glucose on PKC ⁇ translocation in BREC.
  • BREC were grown in tissue culture plates to confluence and treated with normal or high glucose
  • PKC ⁇ in the particulate fraction was determined by Western blotting and a representative blot is shown.
  • the densities of the bands were quantified with Image Quant software and are expressed as percentage of control (100%).
  • the data are expressed as mean + SEM derived from 3 separate experiments. (*p ⁇ 0.05)
  • FIG 13 shows effect of high glucose on PKC ⁇ l translocation in BREC.
  • BREC were grown in tissue culture plates to confluence and treated with normal or high glucose DMEM/plasma for 3 days. Cells were sonicated and PKC was extracted from the particulate fraction by sonication in the presence of 2% Triton-XIOQ. The amount of PKC ⁇ l in the particulate fraction was determined by Western blotting and a representative blot is shown. The densities of the bands were quantified with Image Quant software and are expressed as percentage of control (100%). The data are expressed as mean + SEM derived from 5 separate experiments. ( * p ⁇ 0.05)
  • Figure 14 shows effect of high glucose on PKC ⁇ translocation in BREC.
  • BREC were grown in tissue culture plates to confluence and treated with normal or high glucose DMEM/plasma for 3 days. Cells were sonicated and PKC was extracted from the particulate fraction by sonication in the presence of 2% Triton-X100. The amount of PKC ⁇ in the particulate fraction was determined by Western blotting and a representative blot is shown. The densities of the bands were quantified with Image Quant software and are expressed as percentage of control (100%). The data is expressed as mean + SEM derived from 3 separate experiments.
  • Figure 15 shows effect of MP5 on PKC ⁇ l activation.
  • BREC were pre-treated with 30 ⁇ M MPi) for 2h before exposure to high glucose (25mM/2% plasma) for 3 clays and compared with control samples (25mM/2%plasma).
  • At confluence (1x106 cells) cells were sonicated and PKC was extracted from the particulate fraction by sonication in the presence of 2% Triton-XIOO.
  • the amount of PKC j.3I in the particulate fraction was determined by Western blotting and a representative blot is shown.
  • the densities of the bands were quantified with Image Quant software and are expressed as percentage of control (100%). The data are expressed as mean + SEM derived from 3 separate experiments (*p ⁇ 0.05)
  • Figure 16 shows effect of hyperglyeaemie conditions on I ⁇ B ⁇ degradation in short term culture
  • BREC were grown to confluence and treated with 25mM glucose for 1,2,3, and 4h and compared to 5.5mM glucose as a control.
  • Cells were lysed and iysates analysed by Western blotting for IscB ⁇ . The membrane was stripped and re-probed with ⁇ -actin. The density of each band was quantified and the ratio of IscB ⁇ ;: ⁇ -actin calculated. The ratios are expressed as percentage of control (100%). Representative blots are shown. The data are expressed as mean + SEM of 3 experiments.
  • Figure 17 shows effect of hyperglyeaemie conditions on l ⁇ B ⁇ degradation in long term culture.
  • BREC were grown to confluence and treated with 5.5mM or 25mM glucose for 3 days.
  • Cells were lysed and Iysates analysed by Western blotting for I ⁇ B ⁇ .
  • the membrane was stripped and re-probed with ⁇ -actin.
  • the density of each band was quantified and the ratio of l ⁇ B ⁇ : ⁇ -actin calculated. The ratios are expressed as percentage of control (100%). Representative blots are shown. The data are expressed as mean + SEM of 7 experiments.
  • Figure 18 shows concentration effect of TNF ⁇ on IKB ⁇ degradation under low (5.5mM) glucose conditions.
  • BREC were grown to confluence in low glucose DMEM/"10%plasma and treated with increasing concentrations of TNF (0, 1, 10, lOOOU/ml) for 15min.
  • Cytoplasmic extracts were analysed using Western blotting for IscB ⁇ . The membrane was stripped and re-probed with ⁇ -actin. The density of each band was quantified and the ratio of I ⁇ B ⁇ : ⁇ -actin calculated. The ratios are expressed as percentage of control (100%). Representative blots are shown. The data are expressed as mean + SEM of 3 experiments. (*p ⁇ 0.01)
  • Figure 19 shows concentration effect of TNF on TscB ⁇ degradation under high (25m M) glucose conditions. BREC were exposed to 25mM glucose for 3 days until confluent then treated with increasing concentrations of TNF (O 7 I 7 1O 7 lOOOU/ml) for 15min.
  • Cytoplasmic extracts were analysed using Western blotting for I ⁇ B ⁇ .
  • the membrane was stripped and re-probed with ⁇ -actin.
  • the density of each band was quantified and the ratio of I ⁇ B ⁇ : ⁇ -actin calculated.
  • the ratios are expressed as percentage of control (100%). Representative blots are shown.
  • the data are expressed as mean + SEM of 3 experiments. (*p ⁇ 0.001 )
  • Figure 20 shows time course for TNF-induced l ⁇ B ⁇ degradation under low (5.5mM) glucose conditions.
  • BREC were grown to confluence in 5.5mM glucose and treated with 1000U/ml TNF for O 7 5, 10, 15, 30min.
  • the cells were then lysed and analysed by Western blotting for I ⁇ B ⁇ .
  • the membrane was stripped and re-probed with ⁇ -actin.
  • the density of each band was quantified and the ratio of I ⁇ B ⁇ : ⁇ -actin calculated.
  • the ratios are expressed as percentage of control (100%). Representative blots are shown.
  • the data are expressed as mean + SEM of 2 (5 and 30min) to 5 experiments. Significance of difference between control and treated cells: p ⁇ 0.0001 (ANOVA).
  • Figure 21 shows time course for TNF-induced I ⁇ B ⁇ degradation under high (25mM) glucose conditions.
  • BREC were exposed to 25mM glucose for 3 days until confluent and treated with 1000U/ml TNF for O 7 5 7 1O 7 15, 30min.
  • Cells were lysed and analysed by Western blotting for I ⁇ B ⁇ . The membrane was stripped and re-probed with ⁇ -actin. The density of each band was quantified and the ratio of l ⁇ B ⁇ : ⁇ -actin calculated. The ratios are expressed as percentage of control (100%). Representative blots are shown. The data are expressed as mean + SEM of 2 (5 and 30mm) to 5 experiments. Significance of difference between control and treated cells: pO.OOOl (ANOVA).
  • Figure 22 shows suppression of TNF induced I ⁇ B ⁇ degradation by MP3.
  • BREC were exposed io 25mM glucose for 3 days until confluent (IxIO'' cells). Cells were treated with increasing concentrations of MP3 for 2h before exposure to TNF 10 ⁇ 0U/ml. Cells were lysed and cytoplasmic extracts analysed for l ⁇ B ⁇ levels by Western blotting. Blots were stripped and re-probed with [3-actin. The density of each band was quantified and expressed as I ⁇ B ⁇ : ⁇ -actin as a percentage of control (100%). Results of ? separate experiments are shown.
  • Figure 23 shows suppression or FKC-I translocation in glucose-stimulated mesangiaf cells (a) and in the glomeruli of diabetic rats (b).
  • Mesangial cells were pretreated with MP5 or vehicle (ethanol) for I hour before being incubated with 25 mM glucose for 5 days, Male rats were rendered diabetic with streptozotocin and MP5 or vehicle (ethanol) was administered for 7 days after confirmation of diabetes.
  • the cells and glomeruli were sonicated and particulate traction associated PkC- ⁇ l was determined by Western Plot analysis. High glucose and diabetes increased PKC- ⁇ l in the particulate fraction. MP5 inhibited this effect.
  • Figure 24 shows the effect of ⁇ -oxa-21:3n-3 treatment of diabetic rats on water consumption, urinary output and urine albumin levels. Rats received 40 mg/kg of the fatly acid daily for two weeks. Significance of difference *p ⁇ 0.05.
  • Figure 25 shows that in a mouse model for atherosclerosis, mice treated with MP? have significantly reduced plaque area as compared to control.
  • Collagenase type 1 collagen type Vl, and gelatin type B were from Sigma- Aldrich.
  • Collagenase type IL deoxyribonuclease were from Worthington, Lakewood, NJ, USA.
  • Tumour Necrosis Factor ⁇ was produced by Genentech, Inc (San Francisco, CA, USA) Il had a specific activity of 6x10' U/mg as assessed lor cytotoxicity by lhe supplier on actinomycin- D -treated murine fibrosarcoma cell line (L929), and was >9S% pure using ⁇ he Limulus amoebocyte lysate assay. Lipopolysacchaiide (LPS) i ontaniination wa « ⁇ 0.125 1 PS L /ml.
  • TN 1 F was stored at a concentration of 5x107 L/ml in 5ul aliquots at -20 0 C and was prepared tresh daily in HBSS.
  • Bovine Scrum Albumin was from Boehringcr Manheim, VV Germany, l ⁇ eial calf serum
  • FCS Hank* balanced salt solution
  • HBSS Hank* balanced salt solution
  • RPMI 1640 L-glutamine (20OmM) were from JRI I biosciences, Lenexa, KS, USA.
  • Leupeptin, pepstatm A, benzamidine hydrochloride, PMSF (phenylmethylsultonyl fluoride) were from Sigma-Aldrich.
  • Aprolinin bovine lung, 100,000UzSmI was from Calbiochem, La jolla, CA, USA
  • Rabbit anti-human to Von Willebrand Factor, anti-mouse Ig, (HRP conjugated) was from DAKO Corporation, Carpinle ⁇ a, CA, USA
  • ⁇ nti rabbit Ig (HRP conjugated) was lrom Chemicon. Boronia, VlC.
  • FITC conjugated rabbit IgG, PKC (31, fill, a, b, f, ⁇ antibodies were from Santa Cruz Biotechnology Santa Cruz, CA, USA.
  • ⁇ -actin antibody was from Sigma- Al drich.
  • C6 glioma cell-conditioned media and retinal crude extract were used to support the growth of these cells as these conditions were considered to be optimal for eulturing BREC.
  • C6 glioma cells were obtained from American Type Culture Collection (ATCC), Rockville, MD, USA. They were grown in 75cm 2 culture flasks in 5.5mM DMEM supplemented with 10% plasma, lOOU/rnl penicillin/100 ⁇ g/ml streptomycin, and 4rnM L-glutamine. The media were collected after 3-4 days, and centrifuged at 155Og for lOmin to remove cells. The media were then stored at -20°C to ensure death of any residual C6 glioma cells, and thawed for use in BREC culture media.
  • retinal crude extract After isolation of retinal tissue from fresh cow eyes, the retinas were incubated at room temperature in PBS (1 retina per ml) for 2h. They were centrifuged at 45Og for 5min and the supernatant filtered through a 0.2 ⁇ m filter and used as retinal crude extract.
  • BREC culture media BREC were grown in culture media containing a combination of 20% FCS (heat inactivated in a 56°C water bath for 30min), 30% DMEM (5.5rnM glucose supplemented with antibiotics and 4mM L-glutamine), 10% plasma, 40°/ « Cb conditioned media, and 10j ⁇ i/ml retinal crude extract.
  • the eyes were dissected removing excess fat and muscle from the surface and rinsed in ethanol and PBS I hey were bisected and the retina removed and rinsed in DMEM/HhPhb pH 7.4 Retinas were homogenised 3x at 200-3G0rpm (Mulfifix hornogeraser, Orpington, Kent, UR) and centrifuged at 70Og tor 10m in The resultant pellet was resuspended in PBS and filtered through an 83 ⁇ m filter.
  • Blood vessel fragments were inverted onto collagenase type 1 (lmg/ml)/deoxy ⁇ bonuclease (300 ⁇ g/ml) enzyme mixture and incubated on a rotary shaker lor 25min al 37°C until devoid of pericytes This was then filtered through a 53 um filter and inverted onto DMRM supplemented with 20% FCS. Cells were centrifuged at 45Og for iOmin, resuspended in culture medium supplemented with fungizone (2.5 ⁇ g/ml) and transferred to collagen-coated culture flasks Cells were grown at 37°C in an atmosphere of 5°/ « COz in air and high humidity. Culture media was changed every 2-3 days.
  • HUVRCs were prepared using methods described previously (Bates et al., J Lcukoc Biol 54: 590-5%, 1993) Human umbilical cords were collected immediately after delivery and stored at 4°C tor less than 36h. The umbilical vein was cannulated and washed with HBSS. They were then filled with collagenase type Il ⁇ 0.4mg/ml), clamped and incubated for 2mm in a 37°C water bath. The c ontent" of each vein were collected and the vein flushed through with HBSS to collect any remaining cells.
  • BREC were identified by their growth as a monolayer and their spindle shaped appearance, whereas HUVEC display a cobblestone appearance when confluent. Purity was assessed by Von Willebrand Factor staining (as described by Jaffe ci ai., J CHn Invest 52: 2757-2764, 1973), For this, BREC or HUVEC were grown to confluence on collagen- or gelatin-coated coverslips and fixed with ethanol for 5min at 4°C.
  • Venous blood was collected from healthy donors and placed into tubes containing 25 lU/ml heparin.
  • Blood (6ml) was layered onto 4ml Hypaque-Ficoll media (8% Ficoli 400, sodium diatrizoate and angiograffin, density 1.114) and centrifuged at 56Og for 35min. After centrif ligation, the leukocytes were resolved into two discrete bands with the mononuclear leukocytes (monocytes, T and B lymphocytes) in the top band and neutrophils in the lower band. Red blood cells were at the bottom of the tube and plasma on the top. The lymphocyte layer was gently aspirated and washed twice with Medium 199 for 5min at 56Og. The viability of the cells was >99%, assessed by their ability to exclude trypan blue.
  • T lymphocytes were purified using a modification of the method of Zhang et al. (J Immunol 148: 177, 1992). Tissue culture plates (10cm) were coated with 3ml autologous plasma for 30min at 37°C in a humidified atmosphere of 5% CO: in air. The isolated mononuclear cells were resuspended in 40ml RPMl 1640, supplemented with 20% heat inactivated FCS and 5ml added to each plate. After incubation at 37°C in the CO?. incubator, monocytes adhered to the plastic tissue culture dishes and were therefore depleted.
  • the plates were washed with 10ml RPMl 1640/10% FCS to remove nonadherent T and B lymphocytes and the media collected and centrifuged for 5min at 56Og.
  • the cell pellet was resuspended in 0.8ml RPMl 1640/10% FCS and applied to a ImI syringe packed with nylon wool which was incubated at 37°C in the CO:, incubator. (The column had been pre-equilibrated by passing RPMI 1640/10% FCS through the column at 37°C).
  • T lymphocytes were removed and washed twice with serum-free RPMl 1640.
  • the viability of purified T lymphocytes was >99%, assessed by their ability to exclude trypan blue. Cells were resuspended at a density of 4x10 6 cells/ml.
  • HL-60 cells were obtained from American Type Culture Collection (ATCC), Rockville, MD, USA, and maintained in RPMI 1640 supplemented with 10% heat inactivated FCS, antibiotics and 4mM L-gJutamme. They were incubated at 37°C in a humidified atmosphere of 5% CO2 in air, and kept at a density of ⁇ lxl ⁇ 6 . cells/ml.
  • T lymphocytes and HL60 cells were centrifuged to remove the media and disrupted in sonication buffer.
  • Total cell extracts were prepared by sonicating samples in 150ul of 2% TritonX- 100/sonication buffer (2OmM Tris-HCI, pH 7.4,. 5mM ECITA, 2mM EDTA,. 2mM dithiothreitoi (DTT), lO ⁇ g/ml le ⁇ peptin, lO ⁇ g/ml aprotinin, lO ⁇ g/ml pepstatin A, 1OmM benzamidine hydrochloride, and 1OmM phenylmethylsufonyl fluoride (PMSF)), Samples were sonicated (3 x 10 sec) at 4°C on setting 7, tune 2 using a Heat Systems sonicator (Lab Supply, Sydney, SA) and left on ice for 30min to allow PKC to dissociate from the membranous fraction of the cell.
  • TritonX- 100/sonication buffer 2OmM Tris-HCI, pH 7.4,. 5mM ECITA, 2
  • PKC When PKC is activated it translocates from the cytosol to the membranous fraction of the cell.
  • the amount of PKC on the membranous fraction was determined using Western Blot analysis with PKC isozyme specific antibodies.
  • BREC were grown in 6cm collagen-coated tissue culture plates in culture media. At 40- 50% confluence, cells were treated with DMEM containing either 5.5mM or 25mM glucose and 10% plasma for 3 days until confluent (1x106 cells/plate). Cells were then treated with PMA (10OnM) or vehicle (DMSO, 0.1% v/v) for 5mm before they were harvested. To each plate was added 300 ⁇ l of sonication buffer (see above for composition) and the cells scraped and transferred into centrifuge tubes.
  • BREC were grown to confluence (IxIO 6 ceils/plate) in 6cm collagen-coated tissue culture plates. After treatment with various concentrations of glucose or TNF for different time periods, cells were lysed. To each plate was added 300 ⁇ l of lysis buffer (NP40 0.5% v/v, 2OmM HEPES pH 7.2, 10OmM NaCl 1mM EDTA, 2mM dithiothreitol (DTT), lO ⁇ g/ml le ⁇ peptin, lO ⁇ g/ml aprotmin/lO ⁇ g/ml Sigma 104, lO ⁇ g/ml pepstatin A, 1OmM benzamidine hydrochloride, and 1OmM PMSF) and cells scraped from the plate with a rubber policeman and transferred into eppendorf tubes.
  • lysis buffer NP40 0.5% v/v, 2OmM HEPES pH 7.2, 10OmM NaCl 1mM EDTA, 2m
  • Protein was transferred onto a nitrocellulose membrane using electrophoresis at 100V for 1.5h. Ponceau S staining (0.1% in 5% acetic acid) was used to confirm equal protein load and even transfer of protein to the membrane.
  • the membrane was blocked for Ih at 37°C in blocking buffer (5% skimmed milk, 25mM Tris/HCl pH 7.4,, 10OmM NaCl) then incubated with primary antibody (Table 2.1) diluted in Tris/HCl-Twccn20 (pH 7.4) for 45min.
  • the membrane was washed (3x5min) in blocking buffer + 0.1% Tween- 20 before being incubated for 45m in with horse radish peroxidase conjugated secondary antibody (Table 2.1) diluted in blocking buffer.
  • the membrane was washed again (3x5min) with blocking buffer.
  • the protein bands were visualised using enhanced chemiluminescence. The relative density of each band was determined using Image Quant software, version 3.3 (Molecular Dynamics, Charlottesville, VA,
  • Membranes which were probed for I ⁇ B ⁇ were stripped and reprobed (see 2.12) for ⁇ - actin as a protein loading control. Densitometry scanning facilitated the correction of any unequal protein loading and results were expressed as a ratio of l ⁇ B ⁇ : ⁇ -actin signal.
  • the ⁇ -oxa fatty acids were identified using 1 H and 1 Xl nuclear magnetic resonance spectroscopy. Engineered fatty acid purity was assessed using thin layer chromatography (TLC). 50 ⁇ i of a 2OmM stock solution of the fatty add was spotted onto a silica coated aluminium plate and allowed to dry. The plate was developed in a tank containing diethyl ether:hexane:acetic acid:H2O (65:35:0.5:0.5, v/v). After the solvent front had travelled 16cm, the plate was air dried and exposed to iodine vapour until the lipids could be visualised. There was no evidence of decomposition or degradation of the fatty acids.
  • the fatty add was diluted in serum-free DMEM to the required concentration (5- 3OuM).
  • the final concentration of ethanol was 0.01-0.1%.
  • Control cells were treated with equivalent amounts of ethanol.
  • Cells were pre-treated with the fatty acid for l-2h prior to any other treatment and lysis of cells. After pre-incubation with the fatty acid, cells were maintained in culture media containing 2-10% serum.
  • Bovine retinal endothelial cells were used as a model to examine the ability of novel polyunsaturated fatty acids to target PKC activation under hyperglycaemic conditions. It is known that different cell types express a different spectrum of PKC isozymes. Thus it was essential to firstly establish which PKC isozymes are expressed in BREC and the ability of classical agonists such as PMA to translocate (ie activate) these isozymes from the cytosol to the membrane. Comparisons of PKC isozyme expression were made with different cell types, ie, human umbilical vein endothelial cells (HUVEC), human T lymphocytes and HL60 cells.
  • HUVEC human umbilical vein endothelial cells
  • Bovine retinal endothelial cells were prepared from fresh bovine eyes using methods modified from Wong et al. ⁇ Invest Ophthalmol Vis Sd 28:1767-1775, 1987). Cell culture and culture media preparation are described in Example 1. Isolated retinal endothelial cells were grown in collagen-coated culture flasks at 37°C with 5% CCh in air and high humidity in BREC culture media which was changed every 2-3 days. Stocks were stored for future use at -70 0 C and cells were used in experiments up to passage 5,
  • FIG. 4 shows the expression of PKC isozymes in HIJVEC.
  • the data demonstrate that HiJVEC express PKC a, ⁇ l,. ⁇ ll, b, and ⁇ shown by the dense bands on Western blotting,
  • Venous blood was collected from healthy donors and mononuclear cells were obtained by density gradient centrifugarion as described in Example 1. Mononuclear cells were isolated and T lymphocytes purified by adherence to nylon wool. The cells were cultured in RPMl 1640 supplemented with 10%FCS and antibiotics to a concentration of 4x106 cells/ml, then sonicated in buffer containing and 2% Triton-XIOO. The PKC expression in these preparations was determined by Western blotting.
  • PKC isozyme expression in myeloid HL60 cells HL60 cells were cultured in tissue culture flasks in RPMH 640 supplemented with 10% FCS and antibiotics. The cells were maintained at ⁇ lxl ⁇ 6 cells/ml. The cells (Ix 10 7 ) were sonicated in buffer containing 2% Triton-XIOO and the expression of PKC a, ⁇ l, ⁇ ll, b, ⁇ and ⁇ was determined by Western blotting.
  • PICC isozyme expression varies in different cell types which could account for differences in cellular responses to PKC! activation.
  • BREC were found to express PKC a, ⁇ l, 5 and ⁇ whereas HUVECs contain PKC a, ⁇ l, ⁇ , ⁇ and ⁇ .
  • T lymphocytes express the greatest number of PKC isozymes, including PKC a, ⁇ l, ⁇ ll, ⁇ , ⁇ , and 0.
  • HL60 ceils express PKC ⁇ , ⁇ ll, ⁇ , ⁇ , and ⁇ .
  • the purpose of this study is to attempt to confirm the effect of glucose on PKC isozyme transkx:atk)n/ activation.
  • the isozymes of interest are PKC a, ⁇ l, ⁇ and ⁇ as these have been shown in Example 2 to be expressed in BREC.
  • the main objective of this study was to examine the effect of the engineered PUFA, ⁇ -oxa 21:3n-3 (MP5) on PKC activation in BREC.
  • BREC were isolated from bovine eye retinal capillaries and cultured in tissue culture plates as described in Example 1. They were grown to confluence (ixlO 0 cells) and treated with either 10OnM of PMA or the equivalent amount of diluent for 5min at 37°C. The cells were detached from the plate and sonicated. The particulate (membranous) fraction was isolated from the soluble fraction by eentrifugation at 100,000g for 30min. PKC was extracted from the membranous fraction by sonication in 2% Triton -X 100 and after eentrifugation, the soluble fraction was subjected to Western blot analyses using a panel of PKC isozyme specific antibodies. The density of each band was quantified by Image Quant software (version 3.3).
  • PKC isozyme translocation is shown in Figures 7 - 10.
  • Treatment of BREC with 10OnM PMA for 5min resulted in significant increases in PKC a (249+22.3%, p ⁇ 0.05) and PKC ⁇ l (203+21.5%, p ⁇ 0.01) in the particulate fraction.
  • BREC were grown in tissue culture plates (1 x 10 6 cells) and treated with high (25mM) glucose for 3 days and compared with low (5.5mM) glucose as a control (physiological glucose levels). Cells were scraped from the plate and sonicated. The membranous fraction was isolated and PKC extracted from the membranous fraction by sonication in 2% Triton-XlOO. Western blotting was used for detection of PICC ⁇ , ⁇ l, ⁇ , and ⁇ . The density of each band was quantified by Image Quant software (version 3.3). 1 S 1 S 1 S
  • Figure 15 shows that 30 ⁇ M MP5 significantly inhibited the activation of PKC ⁇ l (37+11.8% reduction). No significant effects of MP5 were seen with respect to PKC a, ⁇ , or ⁇ .
  • PKC isozymes vary in their responsiveness to activation by PMA, a known activator.
  • PKC a appeared to be the most responsive to activation by PMA followed by PKC ⁇ !.
  • PKC ⁇ and ⁇ showed a trend towards activation but this was not statistically significant.
  • Results show that PKC ⁇ l and ⁇ are activated by hyperglycemic conditions in BREC, demonstrated by an increase in PKC translocation after 3 days of treatment with 25mM glucose.
  • PKC ⁇ l showed the greatest increase in activation, supporting its role as the main mediator of the effects of hyperglycemia in these cells.
  • PKC a and ⁇ were not activated by hy perglycaemie conditions in these cells.
  • Pre-exposure with [J-oxa21 3n-3 (MPo) inhibited glucose-induced PKC ⁇ l activation in BREC No significant etlects ot MP3 were seen with respect to PKC «, & or e.
  • NFKP NFKP IS associated with IKB a, [3, or t in its inactive state.
  • IKB kinases are activated which phosphorylate l ⁇ B ⁇ Phosphorylated l ⁇ B ⁇ dissociates from NFKB and is degraded in the cytosol NFKB is thus free Io migrate to the nucleus where it exerts its action Therefore, loss of l ⁇ B ⁇ corresponds to ⁇ F ⁇ B activation.
  • BREC were grown in ⁇ cm culture plates and treated with high (25mM) glucose for various time periods (10-30min, l-4h, 3 days). This was compared to low (5.5mM) glucose as a control (physiological glucose level). At the appropriate time periods, the cells were lysed, the cytosoi collected and analysed for l ⁇ B ⁇ levels by Western blotting. Assessing the loss of l ⁇ B ⁇ is a convenient and validated assay method for NFKB activation.
  • TNF has been shown to be involved in the pathogenesis of diabetic nephropathy. It was therefore of interest to examine the effect of TNF on NFKB activation in the presence of high glucose.
  • BREC were grown to confluence (1x10 b cells) under low (5.5m M) or high (25mM) glucose conditions for 3 days. They were then exposed to 0, 1, 10 and 1000 U/ml TNF for 15min. Cells were lysed and analysed by Western blotting for I ⁇ B ⁇ levels.
  • BREC were cultured in 6cm culture plates until confluent (IxIO 6 cells). They were treated with TNF (lOOOU/ml), for 0, 5, 10, 15 and 30min under low (5.5mM) and high (2SmJVl) glucose conditions for 3 days. Cells were Jysed, the cytosol collected and analysed for the amount of I ⁇ B ⁇ by Western blotting.
  • Figure 20 shows that under low glucose conditions a dense band is seen in unstimulated BREC (0 time) indicating the presence of l ⁇ B ⁇ bound to NFKB in the cytosol.
  • Treatment with lG00U/ml TNF caused a time dependent loss of I ⁇ P ⁇ which was reduced by 64.3+2.8% at lOmin, 82.8+4.4% at 15min, with some recovery of levels by 30m in (67.7+14.3% reduction). This reversal has also been seen previously in TNF- stimulated cells.
  • BREC were grown to confluence (1x10° cells) and exposed to DMEM containing 23mM glucose and 10% plasma tor 3 clays.
  • MP3 was reconstituted in 100% ethanol to a concentration of 2OmM and diluted in serum-free DMEM to concentrations of 5, 10,. 15 and 2O ⁇ JV3.
  • BREC were rinsed twice in serum-free DMEM and pre-treafed with increasing concentrations of MP3 lor 2h before exposure to 100UU/ml FNF for 10- 15min.
  • Control samples were pre -treated with equivalent amounts of vehicle ⁇ ethanol, maximum ol 0.1%, v/v). Cells were scraped from the plate with a rubber policeman and ly ⁇ ed, the i ytosol colli - ⁇ ted and analysed tor l ⁇ B ⁇ levels by Western blotting.
  • Figure 22 shows the results from 3 individual experiments. MP3 dose-dependently inhibited I MF-induced l ⁇ B ⁇ degradation Consistent with the above data, the effect ol TNiF per se was greater at 15min than at lOmin.
  • ⁇ -oxa PLFA, MP3 ( ⁇ -oxa 23 4n-6), suppressed ⁇ he TNF-induced activation of NFKB under high glucose c onditions in bovine retinal endothelial t ells.
  • a concentration effect is demonstrated with 15 ⁇ M and 2OuVI ot MP3 producing the greatest inhibitory effects of l ⁇ B ⁇ degradation.
  • mice (70mg/kg) or vehicle daily for 2 weeks prior to being placed on a high fat diet.
  • the mice were then placed on the high fat diet and continued to receive the MP3 or vehicle every other day for 5 weeks.
  • the mice were then sacrificed, heart isolated, sectioned and stained for examination.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne le traitement de maladies à médiation par la protéine kinase C bêta (PKC-β) ou le facteur nucléaire Kappa B (NFKB), dont, en particulier : (i) le diabète ou ses complications, (ii) les lésions d'ischémie/reperfusion et leurs complications, (iii) l'athérosclérose, (iv) la resténose, (v) le développement tumoral ou (vi) une angiogenèse non souhaitée ou non maîtrisée, grâce à l'administration d'une quantité efficace de (i) un acide gras polyinsaturé (PUFA) comprenant une substitution oxa et/ou thia au niveau de l'une ou de l'autre de ses positions β ou γ ou, encore, des deux ; un PUFA lié par une liaison covalente à un acide aminé ; (iii) un nitroalcène ou un nitroalcyne polyinsaturé ; (iv) un PUFA n-3 ; ou (v) un PUFA n-6, et ce éventuellement en association avec un inhibiteur de l'enzyme convertissant l'angiotensine (ACE). L'invention concerne également une composition pharmaceutique comprenant un inhibiteur de l'ACE et (i) un PUFA comprenant une substitution oxa et/ou thia au niveau de l'une ou l'autre de ses positions β ou γ ou, encore, des deux ; un PUFA lié par une liaison covalente à un acide aminé ; (iii) un nitroalcène ou un nitroalcyne polyinsaturé ; (iv) un PUFA n-2 ; ou (v) un PUFA n-6.
PCT/AU2009/000723 2008-06-10 2009-06-10 Traitement du diabète, de ses complications et de troubles associés WO2009149496A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2008902922A AU2008902922A0 (en) 2008-06-10 Treatment of diabetes and complications thereof and related disorders
AU2008902922 2008-06-10

Publications (1)

Publication Number Publication Date
WO2009149496A1 true WO2009149496A1 (fr) 2009-12-17

Family

ID=41416274

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AU2009/000723 WO2009149496A1 (fr) 2008-06-10 2009-06-10 Traitement du diabète, de ses complications et de troubles associés

Country Status (1)

Country Link
WO (1) WO2009149496A1 (fr)

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012059818A1 (fr) * 2010-11-05 2012-05-10 Pronova Biopharma Norge As Méthodes de traitement au moyen de composés lipidiques
WO2013028501A1 (fr) 2011-08-19 2013-02-28 The University Of Utah Research Foundation Polythérapie au moyen de lipides nitrés et d'inhibiteurs du système rénine-angiotensine-aldostérone
WO2013055899A3 (fr) * 2011-10-11 2013-10-31 Complexa, Inc. Compositions utiles pour le traitement d'une néphropathie et leurs procédés de préparation
US8735436B2 (en) 2009-05-08 2014-05-27 Pronova Biopharma Norge As Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas
US8741966B2 (en) 2007-11-09 2014-06-03 Pronova Biopharma Norge As Lipid compounds for use in cosmetic products, as food supplement or as a medicament
US8759558B2 (en) 2008-07-15 2014-06-24 Pronova Biopharma Norge As Sulphur containing lipids for use as food supplement or as medicament
US9585855B2 (en) 2008-06-19 2017-03-07 The University Of Utah Research Foundation Use of nitrated lipids for treatment of side effects of toxic medical therapies
US9663444B2 (en) 2009-10-02 2017-05-30 Complexa, Inc. Heteroatom containing substituted fatty acids
US9700534B2 (en) 2007-08-01 2017-07-11 University of Pittsburgh—of the Commonwealth System of Higher Education Nitrated-fatty acids modulation of type II diabetes
US9750725B2 (en) 2009-07-31 2017-09-05 University of Pittsburgh—of the Commonwealth System of Higher Education Fatty acids as anti-inflammatory agents
US9790167B2 (en) 2008-05-01 2017-10-17 Complexa, Inc. Vinyl substituted fatty acids
CN108721269A (zh) * 2018-07-10 2018-11-02 广东海洋大学 一种epa与dha混合剂在防治焦虑和快感缺乏方面的应用
US10369125B2 (en) 2008-06-19 2019-08-06 The University Of Utah Research Foundation Method of treating renal system damage
US10537541B2 (en) 2015-10-02 2020-01-21 Complexa Inc. Treatment of focal segmental glomerular sclerosis (FSGS) using therapeutically effective oral doses of 10-nitro-9(E)-octadec-9-enoic acid
US10722481B2 (en) 2015-04-28 2020-07-28 Basf As Substituted fatty acids for treating non-alcoholic steatohepatitis
US11351139B2 (en) 2013-02-28 2022-06-07 Basf As Composition comprising a lipid compound, a triglyceride, and a surfactant, and methods of using the same
US11608342B2 (en) 2015-07-07 2023-03-21 H. Lundbeck A/S PDE9 inhibitors with imidazo triazinone backbone and imidazo pyrazinone backbone for treatment of peripheral diseases
US11925614B2 (en) 2017-12-06 2024-03-12 Basf As Fatty acid derivatives for treating non-alcoholic steatohepatitis

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0302481A2 (fr) * 1987-08-07 1989-02-08 Century Laboratories Inc. Utilisation d'acides gras libres pour la fabrication d'un médicament pour le traitement du diabète mellitus
GB2229363A (en) * 1989-03-20 1990-09-26 Michael John Tisdale Pharmaceutical compositions containing eicosapentaenoic acid.
US5034415A (en) * 1987-08-07 1991-07-23 Century Laboratories, Inc. Treatment of diabetes mellitus
US6274747B1 (en) * 1998-12-23 2001-08-14 Ardenia Investments Ltd. Polyunsaturated fatty acid derivatives and their use
US20020055539A1 (en) * 1996-10-02 2002-05-09 Bockow Barry I. Compositions and methods for treating cardiovascular conditions
US6511670B1 (en) * 1999-04-15 2003-01-28 Societe L'oreal S.A. (poly)thiaalkynoic compounds and pharmaceutical/cosmetic compositions comprised thereof
US20030078299A1 (en) * 1999-09-17 2003-04-24 Antonio Ferrante Anti-cancer nitro- and thia-fatty acids
US20040092590A1 (en) * 2002-09-27 2004-05-13 Linda Arterburn Glycemic control for prediabetes and/or diabetes Type II using docosahexaenoic acid
US20050054731A1 (en) * 2003-09-08 2005-03-10 Franco Folli Multi-system therapy for diabetes, the metabolic syndrome and obesity
US6977271B1 (en) * 2001-08-30 2005-12-20 Health Research, Inc. Method for inhibition of angiogenesis and vasculogenesis
US20060142391A1 (en) * 2001-06-18 2006-06-29 Tadakazu Tamai Ppargamma-activating pharmaceutical composition
WO2006102476A2 (fr) * 2005-03-21 2006-09-28 Vicus Therapeutics Spe 1, Llc Compositions et procedes permettant d'ameliorer la cachexie
WO2006117664A1 (fr) * 2005-05-04 2006-11-09 Pronova Biopharma Norge As Nouveaux derives de dha et utilisation de ceux ci en tant que medicaments
WO2007107869A2 (fr) * 2006-03-23 2007-09-27 Pronova Biopharma Norge As Dérivés lipidiques conjugués

Patent Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0302481A2 (fr) * 1987-08-07 1989-02-08 Century Laboratories Inc. Utilisation d'acides gras libres pour la fabrication d'un médicament pour le traitement du diabète mellitus
US5034415A (en) * 1987-08-07 1991-07-23 Century Laboratories, Inc. Treatment of diabetes mellitus
GB2229363A (en) * 1989-03-20 1990-09-26 Michael John Tisdale Pharmaceutical compositions containing eicosapentaenoic acid.
US20020055539A1 (en) * 1996-10-02 2002-05-09 Bockow Barry I. Compositions and methods for treating cardiovascular conditions
US6274747B1 (en) * 1998-12-23 2001-08-14 Ardenia Investments Ltd. Polyunsaturated fatty acid derivatives and their use
US6511670B1 (en) * 1999-04-15 2003-01-28 Societe L'oreal S.A. (poly)thiaalkynoic compounds and pharmaceutical/cosmetic compositions comprised thereof
US20040254240A1 (en) * 1999-09-17 2004-12-16 Antonio Ferrante Anti-cancer nitro- and thia-fatty acids
US20030078299A1 (en) * 1999-09-17 2003-04-24 Antonio Ferrante Anti-cancer nitro- and thia-fatty acids
US6924309B2 (en) * 1999-09-17 2005-08-02 Children, Youth And Women's Health Service Incorporated Anti-inflammatory nitro and thia-fatty acids
US20060142391A1 (en) * 2001-06-18 2006-06-29 Tadakazu Tamai Ppargamma-activating pharmaceutical composition
US6977271B1 (en) * 2001-08-30 2005-12-20 Health Research, Inc. Method for inhibition of angiogenesis and vasculogenesis
US20040092590A1 (en) * 2002-09-27 2004-05-13 Linda Arterburn Glycemic control for prediabetes and/or diabetes Type II using docosahexaenoic acid
US20050054731A1 (en) * 2003-09-08 2005-03-10 Franco Folli Multi-system therapy for diabetes, the metabolic syndrome and obesity
WO2006102476A2 (fr) * 2005-03-21 2006-09-28 Vicus Therapeutics Spe 1, Llc Compositions et procedes permettant d'ameliorer la cachexie
WO2006117664A1 (fr) * 2005-05-04 2006-11-09 Pronova Biopharma Norge As Nouveaux derives de dha et utilisation de ceux ci en tant que medicaments
WO2007107869A2 (fr) * 2006-03-23 2007-09-27 Pronova Biopharma Norge As Dérivés lipidiques conjugués

Non-Patent Citations (15)

* Cited by examiner, † Cited by third party
Title
ABDI-DEZFULI, F. ET AL.: "Eicosapentaenoic acid and sulphur substituted fatty acid analogues inhibit the proliferation of human breast cancer cells in culture", BREAST CANCER RESEARCH AND TREATMENT, vol. 45, 1997, pages 229 - 239 *
DATABASE PUBMED Database accession no. 12022543 *
DAVIDSON, L. A. ET AL.: "Morphodensitometric analysis of protein kinase C (betaII expression in rat colon: modulation by diet and relation to in situ cell proliferation and apoptosis", CARCINOGENESIS, vol. 21, no. 8, 2000, pages 1513 - 1519 *
HEAD, R. J. ET AL.: "Prevention of nerve conduction deficit in diabetic rats by polyunsaturated fatty acids", AM. J. CLIN. NUTR., vol. 71, 2000, pages 3865 - 392S *
HJERKINN, E. M. ET AL.: "Influence of long-term intervention with dietary counseling, long-chain n-3 fatty acid supplements, or both on circulating markers of endothelial activation in men with long-standing hyperlipidemial-3", AM. J. CLIN. NUTR., vol. 81, 2005, pages 583 - 589 *
LAZAR, H. L. ET AL.: "Pretreatment with angiotensin-converting enzyme inhibitors attenuates ischemia-reperfusion injury", ANN. THORAC. SURG., vol. 73, no. 5, 2002, pages 1522 - 1527 *
LUPI, R. ET AL.: "The direct effects of angiotensin-converting enzyme inhibitors, zofenoprilate and enalaprilat, on isolated human pancreatic islets", EUROPEAN JOURNAL OF ENDOCRINOLOGY, vol. 154, 2006, pages 355 - 361 *
MATSUO, T. ET AL.: "Interaction between a-Linolenic Acid-Enriched Oil and -ACE Inhibitor Concerning the Decrease in Blood Pressure in SHR", JOURNAL OF OLEO SCIENCE, vol. 57, no. 1, 2008, pages 11 - 14 *
OGITA, H. ET AL.: "Eicosapentaenoic Acid Reduces Myocardial Injury Induced by Ischemia and Reperfusion in Rabbit Hearts", J. CARDIOVASC. PHARMACOL., vol. 41, no. 6, 2003, pages 964 - 969 *
OKUMURA, K. ET AL.: "Quinapril Prevents Restenosis After Coronary Stenting in Patients With Angiotensin-Converting Enzyme D Allele", CIRCULATION JOURNAL, vol. 66, 2002, pages 311 - 316 *
REMUZZI, G. ET AL.: "Prevention and Treatment of Diabetic Renal Disease in Type 2 Diabetes: The BENEDICT Study", J AM. SOC. NEPHROL., vol. 17, 2006, pages S90 - S97 *
RHODES, L. E. ET AL.: "Effect of eiaosaperitaenoic acid, an omega-3 polyunsaturated fatty acid, on UVR-related cancer risk in humans. An assessment of early genotoxic markers", CARCINOGENESIS, vol. 24, no. 5, 2003, pages 919 - 925 *
SANGIOVANNI, J.P. ET AL.: "The role of omega-3 long-chain polyunsaturated fatty acids in health and disease of the retina", PROGRESS IN RETINAL AND EYE RESEARCH, vol. 24, 2005, pages 87 - 138 *
THE DIABETES AND NUTRITION STUDY GROUP OF THE SPANISH DIABETES ASSOCIATION (GSEDNU): "Polyunsaturated Fatty Acid Consumption May Play a Role in the Onset and Regression of Microalbuminuria in Well-Controlled Type and Type 2 Diabetic People", DIABETES CARE, vol. 27, no. 6, 2004, pages 1454 - 1457 *
YOSHIJI, H. ET AL.: "The Angiotensin-I-converting Enzyme Inhibitor Perindopril Suppresses Tumor Growth and Angiogenesis: Possible Role of the Vascular Endothelial Growth Factor", CLINICAL CANCER RESEARCH, vol. 7, 2001, pages 1073 - 1078 *

Cited By (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10258589B2 (en) 2007-08-01 2019-04-16 University of Pittsburgh—of the Commonwealth System of Higher Education Nitrated-fatty acids modulation of type II diabetes
US10869850B2 (en) 2007-08-01 2020-12-22 University of Pittsburgh—of the Commonwealth System of Higher Education Nitrated-fatty acids modulation of type II diabetes
US10576051B2 (en) 2007-08-01 2020-03-03 University of Pittsburgh—of the Commonwealth System of Higher Education Nitrated-fatty acids modulation of type II diabetes
US9700534B2 (en) 2007-08-01 2017-07-11 University of Pittsburgh—of the Commonwealth System of Higher Education Nitrated-fatty acids modulation of type II diabetes
US8741966B2 (en) 2007-11-09 2014-06-03 Pronova Biopharma Norge As Lipid compounds for use in cosmetic products, as food supplement or as a medicament
US9790167B2 (en) 2008-05-01 2017-10-17 Complexa, Inc. Vinyl substituted fatty acids
US9585855B2 (en) 2008-06-19 2017-03-07 The University Of Utah Research Foundation Use of nitrated lipids for treatment of side effects of toxic medical therapies
US10568857B2 (en) 2008-06-19 2020-02-25 The University Of Utah Research Foundation Method of treating renal system damage
US10369125B2 (en) 2008-06-19 2019-08-06 The University Of Utah Research Foundation Method of treating renal system damage
US8759558B2 (en) 2008-07-15 2014-06-24 Pronova Biopharma Norge As Sulphur containing lipids for use as food supplement or as medicament
US8735436B2 (en) 2009-05-08 2014-05-27 Pronova Biopharma Norge As Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas
US9750725B2 (en) 2009-07-31 2017-09-05 University of Pittsburgh—of the Commonwealth System of Higher Education Fatty acids as anti-inflammatory agents
US10835518B2 (en) 2009-07-31 2020-11-17 University of Pittsburgh—of the Commonwealth System of Higher Education Fatty acids as anti-inflammatory agents
US10213417B2 (en) 2009-07-31 2019-02-26 University of Pittsburgh—of the Commonwealth System of Higher Education Fatty acids as anti-inflammatory agents
US11723897B2 (en) 2009-07-31 2023-08-15 University of Pittsburgh—of the Commonwealth System of Higher Education Fatty acids as anti-inflammatory agents
US9663444B2 (en) 2009-10-02 2017-05-30 Complexa, Inc. Heteroatom containing substituted fatty acids
WO2012059818A1 (fr) * 2010-11-05 2012-05-10 Pronova Biopharma Norge As Méthodes de traitement au moyen de composés lipidiques
US9394228B2 (en) 2010-11-05 2016-07-19 Pronova Biopharma Norge As Methods of treatment using lipid compounds
EA028535B1 (ru) * 2010-11-05 2017-11-30 Пронова Биофарма Норге Ас Способы лечения с применением липидных соединений
CN103347508A (zh) * 2010-11-05 2013-10-09 普罗诺瓦生物医药挪威公司 使用脂质化合物的治疗方法
US9192600B2 (en) 2011-08-19 2015-11-24 The University Of Utah Research Foundation Combination therapy with nitrated lipids and inhibitors of the renin-angiotensin-aldosterone system
US10010532B2 (en) 2011-08-19 2018-07-03 The University Of Utah Research Foundation Combination therapy with nitrated lipids and inhibitors of the renin-angiotensin-aldosterone system
US10709690B2 (en) 2011-08-19 2020-07-14 The University Of Utah Research Foundation Combination therapy with nitrated lipids and inhibitors of the renin-angiotensin-aldosterone system
WO2013028501A1 (fr) 2011-08-19 2013-02-28 The University Of Utah Research Foundation Polythérapie au moyen de lipides nitrés et d'inhibiteurs du système rénine-angiotensine-aldostérone
US9271952B2 (en) 2011-10-11 2016-03-01 Complexa, Inc. Compositions and methods for treating nephropathy
CN107913263A (zh) * 2011-10-11 2018-04-17 康普莱萨公司 适用于治疗肾病变的组合物和其制备方法
WO2013055899A3 (fr) * 2011-10-11 2013-10-31 Complexa, Inc. Compositions utiles pour le traitement d'une néphropathie et leurs procédés de préparation
US11351139B2 (en) 2013-02-28 2022-06-07 Basf As Composition comprising a lipid compound, a triglyceride, and a surfactant, and methods of using the same
US10722481B2 (en) 2015-04-28 2020-07-28 Basf As Substituted fatty acids for treating non-alcoholic steatohepatitis
US11234948B2 (en) 2015-04-28 2022-02-01 Basf As Substituted fatty acids for treating non-alcoholic steatohepatitis
US11911354B2 (en) 2015-04-28 2024-02-27 Basf Substituted fatty acids for treating non-alcoholic steatohepatitis
US11608342B2 (en) 2015-07-07 2023-03-21 H. Lundbeck A/S PDE9 inhibitors with imidazo triazinone backbone and imidazo pyrazinone backbone for treatment of peripheral diseases
US10537541B2 (en) 2015-10-02 2020-01-21 Complexa Inc. Treatment of focal segmental glomerular sclerosis (FSGS) using therapeutically effective oral doses of 10-nitro-9(E)-octadec-9-enoic acid
US11925614B2 (en) 2017-12-06 2024-03-12 Basf As Fatty acid derivatives for treating non-alcoholic steatohepatitis
CN108721269A (zh) * 2018-07-10 2018-11-02 广东海洋大学 一种epa与dha混合剂在防治焦虑和快感缺乏方面的应用

Similar Documents

Publication Publication Date Title
WO2009149496A1 (fr) Traitement du diabète, de ses complications et de troubles associés
Mouton et al. Obesity, hypertension, and cardiac dysfunction: novel roles of immunometabolism in macrophage activation and inflammation
Markworth et al. Arachidonic acid supplementation enhances in vitro skeletal muscle cell growth via a COX-2-dependent pathway
Wan et al. Leukotriene B4/antimicrobial peptide LL‐37 proinflammatory circuits are mediated by BLT1 and FPR2/ALX and are counterregulated by lipoxin A4 and resolvin E1
Yin et al. Role of mitochondria in programmed cell death mediated by arachidonic acid-derived eicosanoids
Marra et al. Ligands of peroxisome proliferator-activated receptor γ modulate profibrogenic and proinflammatory actions in hepatic stellate cells
Fanara et al. Changes in microtubule turnover accompany synaptic plasticity and memory formation in response to contextual fear conditioning in mice
JP6422778B2 (ja) Ｐｋｃアクチベーターおよびその組合せ
Mata et al. The dynamic inflammatory tissue microenvironment: signality and disease therapy by biomaterials
KR101947785B1 (ko) 섬유화 조직으로부터 정상 조직을 재생하기 위한 조성물
Li et al. Targeting the RhoA-ROCK pathway to regulate T-cell homeostasis in hypoxia-induced pulmonary arterial hypertension
Huang et al. Inhibitors of fatty acid synthesis induce PPARα-regulated fatty acid β-oxidative genes: Synergistic roles of L-FABP and glucose
Castiglione et al. Group I metabotropic glutamate receptors control proliferation, survival and differentiation of cultured neural progenitor cells isolated from the subventricular zone of adult mice
Ni et al. PPARγ attenuates interleukin-1β-induced cell apoptosis by inhibiting NOX2/ROS/p38MAPK activation in osteoarthritis chondrocytes
Koyani et al. 15-deoxy-Δ12, 14-PGJ2 promotes inflammation and apoptosis in cardiomyocytes via the DP2/MAPK/TNFα axis
Reiner et al. 9-Cis retinoic acid protects against methamphetamine-induced neurotoxicity in nigrostriatal dopamine neurons
Chen et al. Osthole regulates TGF-β1 and MMP-2/9 expressions via activation of PPARα/γ in cultured mouse cardiac fibroblasts stimulated with angiotensin II
Simard et al. Investigation of omega-3 polyunsaturated fatty acid biological activity in a tissue-engineered skin model involving psoriatic cells
Jiang et al. Mangiferin inhibits high-fat diet induced vascular injury via regulation of PTEN/AKT/eNOS pathway
Kvirkvelia et al. Prostaglandin E2 promotes cellular recovery from established nephrotoxic serum nephritis in mice, prosurvival, and regenerative effects on glomerular cells
JP2021152087A (ja) Ａｄｏ耐性システアミン類似体およびその使用
Zhang et al. Icariin protects against intestinal ischemia–reperfusion injury
Wang et al. Glycogen synthase kinase-3β inhibition alleviates activation of the NLRP3 inflammasome in myocardial infarction
Park et al. Enantiomers of higenamine inhibit LPS-induced iNOS in a macrophage cell line and improve the survival of mice with experimental endotoxemia
Michaelis et al. Role of cytochrome P450 2C epoxygenases in hypoxia-induced cell migration and angiogenesis in retinal endothelial cells

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09761161

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09761161

Country of ref document: EP

Kind code of ref document: A1